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Anterior cruciate ligament (ACL) injuries may result in significant disability and the poor 
healing capacity of the ACL has led orthopedic surgeons to perform ACL reconstructions 
in most of the cases.  In current clinical practice, autografts, including the bone-patellar 
tendon-bone grafts and hamstring tendons, are the most popular and successful surgical 
replacements for the ACL due to their potential for graft remodeling and integration with 
bone in the knee joint. Allografts and artificial ligaments have also been used for ACL 
reconstruction.  All these methods have their individual drawbacks, such as donor site 
morbidity, postoperative pain, deterioration in tensile properties as well as inflammatory 
reaction. Tissue engineered anterior cruciate ligaments have the potential to overcome 
these drawbacks by using principles of life science and engineering to provide structural 
and mechanical support essential for ligament regeneration. The objective of my current 
research is to evaluate two hypotheses, (1) that knitted biphasic scaffolds can provide 
enough mechanical strength before ligament regeneration and (2) that mesenchymal stem 
cells (MSCs) and fascia wrap can promote anterior cruciate ligament regeneration when 
used on biphasic scaffolds followed by implantation in knee joints. Three stages of 
experiments were designed, firstly, to select the optimal cell source for ACL tissue 
engineering from MSCs, anterior cruciate ligament (ACL) fibroblasts and medial 
collateral ligament (MCL) fibroblasts; secondly, to design and characterize the knitted 
scaffolds for ACL tissue engineering; and lastly, to test the in vivo effects of knitted 
scaffolds in a rabbit model as well as to evaluate the effects of MSC seeding and fascia 
wrap application. In the first stage, MSCs, ACL fibroblasts and MCL fibroblasts were 
compared, with regards to the rate of proliferation, collagen excretion, expression of 
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collagen type I and III as well as alpha smooth muscle actin. MSCs were found to be a 
better cell source than the other two regarding proliferation and collagen excretion. In the 
second stage, biocompatibility, cell adhesion, degradation and mechanical properties of 
knitted scaffolds were evaluated as potential tissue engineered prostheses. After knitted 
scaffolds were found to be suitable for this purpose, they were further tested in a rabbit 
model for ACL reconstruction. Histological assessment was carried out at 4 and 20 weeks 
post operatively. Furthermore, immunohistochemistry, western blot of collagen type I and 
III as well as mechanical properties were examined 20 weeks after implantation. Ingrowth 
of a large amount of fibroblasts was found to surround the knitted scaffolds, which 
showed little sign of inflammation and foreign body reaction at the 4 and 20 weeks time 
points. Ligament explants were positively stained with antibodies for collagen type I and 
III. Tissue engineered ligaments remained intact after 20 weeks’ implantation in most of 
the cases, though maximal loads and stiffness of them were still lower than normal ACL. 
Both the amount of collagen type I and collagen type III in group III (MSC seeding/fascia 
wrap) and IV (fascia wrap) were significantly higher than that in group II (MSC seeding), 
which was much higher than that in group I (scaffold only). Results showed that MSC 
seeding could promote synthesis of collagen type I and collagen type III, while fascia 
wraps have even stronger effects than MSC seeding. Both MSC seeding and fascia wrap 
did not further enhance ultimate tensile load and stiffness. For future work, the use of 
scaffolds with improved mechanical properties in combination with MSC seeding, fascia 
wrap, and growth factors may improve ACL reconstructions.  
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The incidence of anterior cruciate ligament (ACL) injuries has increased with increasing 
popularity in sport activities over the years. The prevalence of anterior cruciate ligament 
injuries is about 1 per 3,000 Americans [1]. About 200,000 Americans required 
reconstructive surgery of ligaments in 2002 with total expenditure exceeding five billion 
dollars [2, 3], with even higher costs incurred in loss of man-hours of work, healthcare 
and social benefits. Anterior cruciate ligament injuries may result in significant disability 
and joint dysfunction, which may consequently lead to injury of other tissues, such as the 
meniscus with subsequent development of degenerative joint disease [4]. The poor healing 
capacity of the ACL has led orthopedic surgeons to perform ACL reconstructions in most 
of the cases.  In current clinical practice, autografts, including the bone-patellar tendon-
bone grafts and hamstring tendons [5], have been the most popular and successful surgical 
replacements for the ACL for their potential for graft remodeling and integration into the 
joint [6]. Nevertheless, donor site morbidity is a major concern when utilizing autografts. 
Autografts are occasionally not available for use for repeat surgery or infection. The use 
of allograft avoids donor site morbidity, reduces surgical time and minimizes 
postoperative pain. However, the decrease in tensile properties during sterilization and 
preservation as well as risk of inflammatory reaction has been a concern [1]. The use of 
synthetic ligament replacements has gained some popularity in limited conditions in the 
late 1980s, because they do not involve the sacrifice of autogenous tissues and as such, 
minimize the associated morbidity and risk of disease transmission. At the same time, they 
permit a simpler and easier reconstructive technique as well as a more rapid rehabilitation, 
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as they do not lose their strength during tissue revascularization and reorganization.  For 
artificial ligament prostheses, the results of ACL reconstruction deteriorate with time, due 
to material degradation, foreign body reaction and related inflammation. Furthermore 
ACL prostheses that do not induce tissue ingrowths will shield mechanical loading and are 
prone to fail in the long run, due to synovitis, effusion, arthritis, or mechanical 
deterioration of the prosthesis [7]. These grafts have yet to display the strength or 
performance of human tissue, which is another important hurdle for broad usage in 
clinical practice. 
 
Research for a potential tissue engineered anterior cruciate ligament has been going on for 
some time, with the hope of overcoming the present problems. This revolutionary 
approach requires the use of biocompatible and biodegradable scaffolds, which provide 
structural and mechanical support essential for ligament regeneration. Our two hypotheses 
for this study are; first, knitted biphasic scaffolds can provide enough mechanical strength 
before ligament regeneration; second, mesenchymal stem cells (MSC) and fascia wrap can 
promote anterior cruciate ligament regeneration when used on knitted biphasic scaffolds 
followed by implantation in the knee joint. 
 
1 .1  Anterior cruciate ligament 
1.1.1 Knee Anatomy 
The knee joint is made of bony structures, cartilage surfaces, meniscus, synovium, capsule, 
ligaments and surrounding muscles (Fig 1). The knee consists of the distal femur, the 
proximal tibia and the patella. As the fibula has migrated distally during embryologic 
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development, it is not part of the joint. The distal femur takes the form of two condyles, 
which are separated by the intercondylar fossa. The intercondylar fossa is the proximal 
attachment site for the anterior cruciate ligament and posterior cruciate ligament. Like the 
distal femur, the proximal tibia consists of two condyles (also known as tibial plateau), the 
medial condyle and lateral condyle. The meniscus found on the proximal tibia serves as a 
cushion between tibia and femur. The patella protects the femoral condyles in flexion, 
transmits force from quadriceps across the femur, and increases stability of the knee [8].  
The knee joint is covered by a capsule starting from femur to tibia, some of which 
becomes the arcuate ligament [8]. Five peripheral ligaments (medial collateral ligament, 
the posterior oblique ligament, the arcuate-popliteus corner, the lateral collateral ligament 
and the anterolateral femorotibial ligament), together with the two cruciate ligaments, 
stabilize the knee passively [9]. 
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1.1.2 ACL anatomy  
The cruciate ligaments are parallel bands of regularly oriented, dense connective tissue 
that connect the femur and tibia. They are surrounded by a mesentery-like fold of 
synovium that originates from the posterior intercondylar area of the knee and completely 
envelopes the ligaments. Hence, while the anterior cruciate ligaments are intraarticular, 
they are also extrasynovial. The ACL starts from a fossa on the posterior aspect of the 
medial surface of the lateral femoral condyle and terminates at another fossa in front of 
and lateral to the anterior tibial spine of the tibia (Fig 2) [10]. The cruciate ligaments are 
attached to the femur and tibia, not as a singular cord but as a collection of individual 
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fascicles that fan out over a broad flattened area. The ACL is made of two bands, the 
anoteromedial band and posterolateral bund. The anteromedial band is primarily tight 
throughout flexion and extension, which makes it even tighter as the knee is flexed. The 
posterolateral band is tight in extension and becomes quite relaxed as the knee is flexed 
[11]. 
 
Figure 2 Side view of ACL in flexion and extension 
 
The cruciate ligaments are made up of multiple collagen fascicles [12]. Fibrillar collagen 
that gives the ligament its high tensile strength is synthesized by fibroblasts. The collagen 
molecule is a glycine-rich triple helix. They assemble sequentially into microfibrils, 
subfibrils, and fibrils (20 to 150nm in diameter) before forming fibers (1-20μm in 
diameter) with cross-links to each others and further make up a subfascicular unit (100-
250μm in diameter). These subfascicular units are surrounded by a loose band of 
connective tissue known as the endotenon. Three to twenty subfasciculi subsequently 
form a fasciculus, (from 250μm to several millimeters in diameter), which are surrounded 
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by an epitenon. This interfascicular connective tissue also supports the neurovascular 
elements of the ligament [13]. These individual fascicles are either oriented in a spiral 
fashion around the long axis of the ligament or they pass directly from the femur to the 
tibial attachment. The entire continuum of fascicles is surrounded by the paratenon, a 
connective tissue cover similar to but much thicker than the epitenon [10]. Fibroblasts also 
enzymatically break down and remove old collagen as part of a renewal process. 
 
ACLs attach to the femur and tibia via collagen fibers [14]. The abrupt change from 
flexible ligamentous tissue to rigid bone is mediated by a transitional zone of 
fibrocartilage and mineralized fibrocartilage. This alteration in microstructure from 
ligament to bone, allows a gradual change in even distribution of stress [13]. 
 
The major blood supply to the ACLs arises from the ligamentous branches of the middle 
genicular artery as well as some terminal branches of the medial and lateral inferior 
genicular arteries [15]. ACLs are innervated by branches of the tibial nerve (posterior 
articular branch of the posterior tibial nerve) [16].  
 
In order to successfully reconstruct an ACL, it is necessary to understand the anatomy, 
orientation and attachment sites of the normal ligament. In the reconstruction of the ACL, 
the graft must be positioned so as to minimize the length changes within the ligament, 
which occurs as the knee is flexed and extended [10]. 
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As ACL fibroblasts do not have unique markers, ligaments have been evaluated on the 
presence of a combination of factors, such as the extracellular matrix components 
(collagen I and III, elastin, fibronectin, decorin, and biglycan), relative ratio of collagen 
type I to type III (6-8 folds), types and amounts of reducible cross-links, cell morphology 
and ultrastructure of collagen network [3]. 
 
1.1.3 ACL Kinematics and Mechanics 
The basic movement between the femur and tibia is a combination of rolling and gliding, 
as well as automatic and voluntary rotation. With the loss of cruciate integrity, as well as 
combined lesion of three or more of these ligaments, which often happens simultaneously 
in an injury, complex pathologic instability is inevitable and without surgical intervention 
disability will probably ensue [9]. A good understanding about kinematics of the cruciate 
ligaments is essential for surgeons performing the reconstruction. 
 
Fiber recruitment of the cruciate ligaments involves the relative constant tension of the 
fibers spanning the isometric points and progressive recruiting of the non-isometric bulk 
of ligament fibers [9]. The fiber crimps in the ACL allow for 7% to 16% of creep prior to 
permanent deformation and ligament damage. The ACL can withstand cyclic loads of 
approximately 300 N for about 1.5 million times per year. It is also regularly exposed to 
tensile forces ranging from 67 N (for ascending stairs) to 630 N (for jogging) [17], while 
its maximal tensile load is 1,730 N [18]. In general, the Young’s modulus value for human 
anterior cruciate ligament is 111MPa, ultimate tensile strength is at least 38MPa [18], 
while ultimate mechanical properties of ligaments generally increase during development 
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and eventually diminish with aging [19]. The maximum strain that a ligament can endure 
before failure is between 12-15% strains [20].  
 
1.1.4 Current therapies  
As mentioned earlier, ruptures of the ACL and associated ligaments will lead to 
degenerative changes in knee joints. However, it does not mean that all the ACL ruptures 
have to be reconstructed, as features such as patient age and activity level are quite 
important. One third of the cruciate lesions are only partial tears, with some of the 
functional bands of that ligament being left intact. Almost half of the patients with ACL 
ruptures could be treated adequately by conservative therapies with results equivalent to 
those obtained by surgical measures. Lifestyle, age, instability and cooperation are to be 
considered before therapy [21]. Usually isolated and partial lesions of the ACL are 
amenable to conservative treatment, but total ruptures of the ACL and severe associated 
injuries within the knee joint should be treated surgically, mainly with ACL reconstruction, 
with ligament repaired, capsule sutured, and/or broken meniscus removed [11]. 
 
In current clinical practice, the most popular and successful surgical replacements for the 
ACL have been autografts, including the bone-patellar tendon-bone graft [22] and 
hamstring tendon [5], because of their potential for graft remodeling and integration into 
the joint [6]. Donor site morbidity is a major concern when utilizing autografts and 
autografts are occasionally not available for use as a result of repeat surgery or infection. 
The use of allograft avoids donor site morbidity, shortens surgical time and diminishes 
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postoperative pain. However, the deterioration in tensile properties with sterilization and 
preservation as well as risk of inflammatory and disease reaction has been a concern [1].  
 
The use of synthetic ligament replacements had gained some popularity in late 1980’s, but 
in limited conditions only. They do not involve the sacrifice of autogenous tissues and as 
such minimizes the associated morbidity and risk of disease transmission. At the same 
time, they permit a simpler, easier reconstructive technique and a more rapid rehabilitation, 
as they do not lose their strength during tissue revascularization and reorganization. Both 
braided polytetrafluoroethylene fibers (Gore-Tex) ligament and knitted polyethylene 
terephthalate (Stryker Dacron) ligament prostheses have received general device releases 
from the Food and Drug administration (FDA) as permanent prosthetic devices, but they 
have not been used for a long time [7]. For both Gore-Tex and Dacron ligament 
prostheses, the results of ACL reconstruction deteriorate with time, due to material 
degradation, foreign body reaction and related inflammation. Furthermore, ACL 
prostheses that do not induce tissue ingrowth will shield mechanical loading and are prone 
to fail in the long run, due to synovitis, effusion, arthritis, or mechanical deterioration of 
the prosthesis [7]. The Leeds-Keio prosthesis, which is composed of polyester with an 
open-weave tube to promote fibrous growth, has been popular outside the United States. 
This device has been shown to host collagenous tissue ingrowths and improves 
mechanical properties after implantation [7]. The usage of Leeds-Keio prosthesis is 
limited due to the high incidence of chronic foreign body inflammation, particulate-
induced synovitis, some particle shedding into lymph nodes, and complete graft rupture 
[23]. Of 855 prosthetic ligaments tracked for 15 years, 40%-78% failed owing to wear 
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debris, tissue reactions, and mechanical limitations [24]. Except for their own drawbacks 
and subsequent changes after implantation, these grafts have yet to display the strength or 
performance of human tissue, which is another important hurdle for broad usage in 
clinical practice (Table 1).  
 
Table 1 Mechanical properties of materials used in ACL reconstruction 
 
 
1.1.5 Requirements of scaffolds for ACL reconstruction 
The ideal scaffolds for ACL reconstruction should meet several requirements 
a. Biocompatible and biodegradable  
b. Similar initial strength with normal ACL  








Human ACL 2160 ± 157 [18] 306 [25] 
242 ± 28 [26] 
~ 33 [26] 111MPa [18] 
Human hamstring 
graft 
3790 – 4140 
[25] 
776 [25]   
Human patellar-
tendon graft 












1500 [27] 36 [27]   
 
--------------------------------------------- Introduction-------------------------------------------  




                                                                                                                                             
                                                                                                                                                  
  
c. Controlled and gradual mechanical strength loss in degradation with 
simultaneously increased strength from regenerated tissue 
d. Young’s modules matched with normal 
e. Not to disrupt the potential ACL regeneration  
It is a pity that there is no satisfactory prosthesis at present, though much work has been 
done on it.  
 
1 .2   Tissue engineering 
1.2.1 Definition 
Tissue engineering is an interdisciplinary field that applies principles of engineering and 
the life sciences toward the development of biological substitutes that restore, maintain, 
and improve the function of damaged tissues and organs [28]. Since the early 1990s, much 
development has been achieved in this popular field, especially in tissue-engineered bone, 
cartilage, liver, kidney, etc. Tissue engineering uses the techniques of cell biology, 
engineering, materials science and surgery to fabricate new functional tissues using cells 
and a matrix or scaffold which can be natural, man-made or a composite of both. Tissue 
engineering has the chance to achieve more progress with the help of newly developed 
techniques and concepts from many scientific fields, especially cell biology and materials 
science. Today, a lot of effort has been made to generate new, natural, permanent tissue 
replacements by creating implantable devices composed of tissue-specific cells on 
synthetic biodegradable polymer scaffolds [29]. 
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1.2.2 Functional Tissue Engineering  
The ideal matrix should essentially be biocompatible, and is completely absorbable while 
leaving behind a totally natural tissue replacement following degradation of the polymer 
[30]{Guilak, 2002 512 /id}. Furthermore, the matrix should be easily and reliably 
reproduced into a variety of shapes and structures that retain its shape when implanted. As 
a vehicle for cell delivery, the matrix should provide mechanical support for a duration so 
as to maintain a space for tissue to form [29]. 
 
Tissue engineering often uses cells, biomaterial scaffolds, biochemical and physical 
regulatory signals in various ways to engineer tissues in vitro and in vivo. The most often 
used strategy is to mimic the in vivo normal healing process or embryonic process to 
fabricate a new tissue [3]. The essential components are the presence of reparative cells, a 
structural template, facilitated transport of nutrients and metabolites, a provision of 
molecular and mechanical regulatory factors. An envisioned scenario of clinically relevant 
tissue engineering involves the use of autologous cells, biodegradable scaffolds (Designed 
to serve as a temporary structural and logistic template of tissue development) and 
bioreactors (designed to control the cellular environment) [3]. 
 
1.2.3 Progresses and challenges in tissue engineering 
In recent years there has been remarkable progress in tissue engineering, not only in 
regeneration  of nerve [31], liver, myocardium, pancreas, bone, cartilage, skin and laminin 
as well as myocardial revascularization, but also in the understanding of biological 
principles, such as cell division, cytology, metabolism, stem cells and even in human 
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cloning [31]. Research on biodegradable prostheses for ACL ligament reconstruction has 
been going on for some time, with the hope of overcoming the present problems. Most of 
them have been with the use of biological and synthetic polymers which are 
biocompatible and degradable. Though there are many reports on tissue engineered ACLs, 
only a few of them have been used in vivo for ACL reconstruction (Table 2). Collagen and 
polylactic acid (PLA) are the most often used. Fibroin (silk) ACL scaffold have shown 
promising results [26], but no further in vivo test has been reported. Conceptually in vitro 
cultured tissue engineered ligament with two bone ends would be ideal, as what has been 
reported [32], but there is little further progress reported.  
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Table 2 In Vivo studies of tissue engineered ACLs   


















10MPa (20.4%) Dunn, M.G.  
1992 [33] 
Collagen fiber PLA matrix Rabbit 
4w 


































 Laitinen, O. 
1993 [37] 
 
--------------------------------------------- Introduction-------------------------------------------  
                                                                                                                                  
 
 
                                                                                                                                           15 
                                                                                                                                             
                                                                                                                                         
                                                                                                                                                 
In general, progress in ligament tissue engineering has been rather slow. This can be 
attributed to several factors: 1) ACLs have to undergo complex and multidirectional 
mechanical forces in-situ, to date no scaffold has been reported to be able to reconstruct 
ACL to handle similar mechanical loadings in vivo; 2) following ACL rupture the blood 
supply will be disrupted, this will impede the regeneration of ACLs; 3) the transitional 
fibrocartilage zone between bone and ligament poses a great challenge to reconstitute with 
current techniques; 4) significant changes of cytokine profiles after ACL injuries  could 
lead to the difficulties in ACL regeneration [38]; 5) inability in current tissue engineering 
techniques to restore the stretch-sensitive mechanoreceptors in ACL that trigger muscle 
contractions that protect the knee from extremes of motion [39].  
 
Currently, most of all attention is paid to the first difficulty mentioned above, i.e. to 
improve the mechanical properties of scaffolds to match that of the ACL. Except for 
biocompatibility, there are several technical hurdles to overcome before we can get 
scaffolds with good mechanical properties:  
a. initial mechanical properties of scaffolds should match to ACL, in terms of 
ultimate tensile load and strength, linear stiffness, visco-elasticity, Young’s 
modulus, etc. 
b. TE ACL structures should withstand multi-directional stresses without deforming 
in vivo, while in vitro tests only evaluate the tissues along the direction of loading. 
c. The mechanical properties of scaffolds will change dramatically with enlarged 
cross-section area after tissue ingrowth and material degradation in a way not well 
controlled.  
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d. Mechanics of tissue engineered ACLs often drops before mass degradation and 
leads to quick loss of initial properties  
e. Creeping (Visco-elasticity) is common for polymers and textile structures, which 
would lead to laxity of scaffolds and loss of their initial functionality.   
 
1.2.4 Cell sources 
1.2.4.1 Selection of cell sources for ligament reconstructions 
As mentioned earlier, cells are essential to fabricate tissues in vitro and in vivo. The 
potential cell sources for use in the development of a tissue engineered anterior cruciate 
ligament are as follows: ACL fibroblasts, medial collateral ligament (MCL) fibroblasts 
[40], mesenchymal stem cells (MSCs) and embryonic stem cells (ESC). While the ethical 
debate on embryonic stem cells continues [41], the use of ESCs still harbors unresolved 
issues, such as animal feeder layers, potential for uncontrolled differentiation and 
difficulty in in vitro expansion has restricted their use in tissue engineering applications 
[42]. On the other hand, adult MSCs and other tissue-specific stem cells are present in 
large quantities in the human body; hence, there are lesser ethical and technical issues 
involved. Apart from that they have the potential to differentiate into a variety of 
mesenchymal cell phenotypes, including osteoblasts, chondroblasts, myoblasts and 
fibroblasts [43]. MSCs can also be easily obtained just by a simple aspiration procedure of 
the iliac crests, followed by in vitro expansion to large quantities [44, 45]. MSCs have 
been successfully used to promote the repair of a number of tissues, including tendon [46], 
bone [47] and possibly muscle [48]. Woo et al (1999) reported that MSCs can promote 
ligament regeneration and as such play an active role in ACL regeneration [49].  
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Ligament healing may be accelerated secondary to the cellular interaction between local 
tissue host cells and donor cells, while extracellular matrix is being excreted [50]. To our 
knowledge, there is little published data comparing these three cell types, which are of 
fundamental importance to tissue engineering applications. Previous studies on these three 
types have been based on different species at different ages, cultured with different 
protocols and as such it would be very difficult to compare the results. In this current 
study, it is important to compare the three cells types harvested from the same donors, 
prior to usage in tissue engineering studies. The objective of the current study was to 
evaluate the rate of cell proliferation and collagen expression of ACL fibroblasts, MCL 
fibroblasts and MSCs. Subsequently, after the identification of the optimal cell source, the 
goal was to examine its role as a donor cell and its survivability in the knee joint, 
particularly in an anterior cruciate ligament construct. The longer the donor cells are able 
to survive, the more effective it would be in contributing to tissue repair and regeneration.  
 
1.2.4.2 Mesenchymal stem cells (MSCs)  
Mesenchymal stem cells are a group of pluripotent progenitor cells in the embryo whose 
progeny eventually gives rise to skeletal tissues: cartilage, bone, tendon, ligament, marrow 
stroma and connective tissue [51].  Unmanipulated bone marrow contains mixtures of 
mesenchymal progenitors, some possessing an unrestricted potential for mesenchymal 
differentiation with others showing commitment to one or perhaps two lineages. Both 
intrinsic and extrinsic factors control their developmental pathways to different 
mesenchymal tissues. MSCs also exist broadly in adult mesenchymal tissues, such as bone 
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marrow, periosteum, fat, muscle, etc [52]. Bone marrow derived MSCs were initially 
isolated by their adhesive properties to tissue culture surfaces [53] and since then, many 
protocols on isolation and purification have been proposed [54]. Mesenchymal stem cells 
used in tissue engineering are usually groups of heterogeneous cells, with different 
morphologies, proliferation rates, and differentiation abilities [55-57].  As there are lots of 
concerns about the use of embryonic stem cells (ESCs) in both clinical practice and 
research [41], the use of MSCs could effectively circumvent the current ethical concerns 
about human embryo research. Another advantage of the use of MSCs over ESCs is that 
MSCs could only differentiate into mesenchymal lineages, thus minimizing the concerns 
about unclear pathways and uncontrolled endpoints with ESCs, though there is still a 
controversy about the possibility for MSCs to cross lineage boundaries [58].   
 
1.2.4.3 Allogeneic VS autologous 
Main considerations of cell seeding are seeding efficiency, convenience, immunological 
response and potential future human application. While there is no report about seeding 
efficiency between allogeneic and autologous cell seeding, allogeneic cell seeding is more 
convenient than autologous seeding. For potential future application, allogeneic cell 
seeding could provide a more abundant source of younger cells with shorter preparation 
times. Bone marrow mesenchymal stem cells also incur little immuno-response by 
inhibiting the response of naive and memory antigen-specific T cells to their cognate 
peptide [59]. Some clinical applications have been reported without immunological 
response [60]. In general, allogeneic MSC seeding is preferred.  
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1.2.5 Materials for tissue engineering 
1.2.5.1 Requirement for tissue engineering 
Tissue engineering generally requires the use of a porous biodegradable scaffolds, which 
serve as three-dimensional templates for initial cell attachment and subsequent tissue 
formation both in vitro and in vivo [29]. The biodegradability of the scaffolds allows them 
to be totally replaced by new synthesized functional tissues. Ideal scaffolds used in tissue 
engineering should meet five requirements: (i) high porosity and optimal pore sizes with 
interconnection among individual pores for cell growth and transmission of nutrients and 
metabolic waste; (ii) biocompatible and biodegradable with controlled degradation mode 
and rate to match tissue regeneration; (iii) suitable surface properties for cell adhesion, 
proliferation, and differentiation, as well as extracellular matrix maturity: (iv) mechanical 
properties to match target tissues; (v) ease of processing into various shapes and sizes by 
solid free form fabrication [61].  
 
1.2.5.2 Biological polymer  
Materials which could meet the requirements mentioned above are mainly from polymer, 
either natural or synthetic. Much attention has been paid to biological polymers in the past 
decades, including collagen, silk, polysaccharides, such as alginate, agarose, 
chitin/chitosan, hyaluronan, etc.  
 
1.2.5.2.1 Collagen  
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Collagen forms the most substantial group of structural proteins in connective tissues and 
represents about one third of total body proteins with more than 27 sub-types [62]. 
Collagen is made of highly repetitive triple helices leading to significant homogeneity in 
secondary structure. So far, collagen is the most intensely studied biological polymer with 
potential biomedical usage [63]. Since collagen accounts for more than 80% of the dry 
weight of a normal ligament [64, 65], it is reasonable to reconstruct ACL with it. There 
are many reports on ACL reconstruction and tendon repair with collagen-based constructs 
[35, 66, 67]. In general, collagen used in laboratories is derived from the bovine 
submucosa and intestine [63, 65], as well as mouse tails in small quantities. Naturally 
derived collagen has to be processed so as to improve its mechanical strength and to slow 
down the degradation rate by cross-linking and the removal of antigenic response. 
Chemical cross-linking is often used, including  immersion in aldehyde solution and 
chromium trioxide [63, 65]. Collagen is degraded mainly by lysosomal enzymes [68] 
while collagenase also participates to some extent [63]. The pure triple helical collagen 
molecule does not elicit a strong antigenic response when compared with associated 
cellular debris, ground substance, or the associated nonhelical telopeptide region of the 
collagen molecule [63]. Many methods have been reported to dissociate, purify and 
reconstitute collagen to achieve this aim [69, 70]. Gelatin is a degradation product of 
collagen and has similar properties with collagen. In general, good biocompatibility and 
ease of processing are advantages, while low mechanical strength, shrinkage, possibility 




--------------------------------------------- Introduction-------------------------------------------  
                                                                                                                                  
 
 
                                                                                                                                           21 
                                                                                                                                             
                                                                                                                                         
                                                                                                                                                 
1.2.5.2.2 Silk 
Silks are generally defined as protein polymers that are spun into fibers by silkworms, as 
well as spiders, scorpions, mites and even flies. Silks from different sources have different 
amino acid composition and mechanical properties. Similar to collagen with repeated 
triple helices, silk is characterized by a highly repetitive β-sheet that leads to significant 
homogeneity in secondary structure [71]. Silk from B. mori silkworm is the largest and 
most stable source that has been commercialized for a long time. Silk comprises of a 
fibroin core and a glue-like sericin cover. Unique mechanical properties, as well as 
biocompatibility, slow degradation time and options for genetic control, make it suitable 
for ligament tissue engineering [72]. The extraordinatory mechanical properties and 
enhanced environmental stability of silk fibers are due to the high homogeneity in 
secondary structure (β-sheet), extensive hydrogen bonding, the hydrophobic nature of 
much of the protein, and the crystallinity.  Silk undergoes proteolytic degradation at a 
variable rate dependent on the environmental conditions. Silk fibers lose the majority of 
their tensile strength within 1 year in vivo, and fail to be recognized in 2 years [73-75]. 
Encouraging results from silk-based ACL tissue engineering constructs have been 
reported [76]. Usually the glue-like sericin in silk is the major cause of adverse problems 
with biocompatibility and hypersensitivity [77-79]. Though many successful clinical 
applications have been reported, it is still difficult to assess the biological responses with 
the absence of detailed characterization of the fibers used including the extent of 
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1.2.5.2.3 Polysaccharides 
Polysaccharides are polymers of monosaccharide units. The monomers of a 
polysaccharide are usually all the same (called homopolysaccharides), though there are 
exceptions (called heteropolysaccharides). In some cases, the monomeric units are 
modified monosaccharides. Polysaccharides differ in the composition of the monomeric 
unit, the linkages between them, and the ways in which branches from the chains occur. 
Except for the demand from tissue engineering for new scaffolds materials with 
controllable biological activity and different degradation kinetics factors, two other factors 
have contributed to growing usage of polysaccharide based tissue engineering scaffolds 
[80]: first is the large information on the critical role of saccharide moieties in cell 
signaling schemes and in the area of immune recognition; second has been the recent 
development of new synthetic techniques with the potential for automated synthesis of 
biologically active oligosaccharides, which may eventually allow us to decode and exploit 
the language of oligosaccharide signaling [63]. Polysaccharides could form gels with 
hydrogen-bond and/or iron through a number of mechanisms influenced by the 
monosaccharides as well as the presence and nature of substitute groups. The gel forming 
abilities also contribute to their growing tissue engineering applications. 
 
1.2.5.2.4 Alginate 
Alginate, a polysaccharide, produced from seaweed in 1940, is a product of a neutralizing 
reaction between alginic acid and caustic soda [81]. Calcium, sodium, and ammonium 
alginates have long been used as foams, clots or gauzes for absorbable surgical dressings, 
however, impuries of alginate have been a pertinent hurdle related to biocompatibility. 
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Despite a handful of purification procedures including filtration, precipitation and 
extraction have effectively removed most of impurities [82],  the duration of graft function 
and the fibrous tissue overgrowth are two main concerns for further applications [83]. 
 
1.2.5.2.5 Agarose 
Agarose, a polysaccharide composed of alternating units of galactopyranosyl and 3,6-
anhydrogalactopyranosyl units, is created by purifying agar. When heated and cooled, it 
forms a gel that is used as a support for many types of electrophoresis and immuno-
diffusion. It is porous and solid in different grades. Its gel forming ability has been well 
used to entrap tissue engineering endocrine cells and cell injection [84]. Agarose has also 
been used to study the effects of dynamics on cells, mainly on chondrocyte culture [85, 
86], but the Young’s modulus usually are not good enough for ligament tissue engineering 
[87-89]. 
 
1.2.5.2.6  Chitin  
Chitin, poly [ß- (1–4)-2-acetamido-2-deoxy-D-glucopyranose], is one of the most 
abundant natural polymers. It occurs in animals, particularly in crustacea, molluscs and 
insects as an important constituent of the exoskeleton and in certain fungi as the principal 
fibrillar polymer in the cell wall [90]. The main sources of material for the laboratory 
preparation of chitin are the exoskeletons from various crustacea, principally crab and 
shrimp. Various procedures have been adopted to remove the impurities in raw chitins and 
no standard process has been developed. HCl is most frequently used for demineralization 
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while NaOH is for deproteinization. However, other methods can be used and the order in 
which these two steps are carried out has varied between different works, although in most 
instances, deproteinization has been carried out prior to demineralization.  
 
Currently, chitin has a diverse usage in health care, particularly, in wound care [91], 
cartilage tissue engineering [92], bone tissue engineering [93] and drug delivery [94]. 
Chitin sutures have been reported biocompatible [95, 96] and lost 45% of its tensile 
strength by 14 days [97]. When braided chitin scaffolds were used for tendon repair, they 
lost their tensile strength more rapidly than those from poly-caprolactone and Poly-lactic 
acid [98].  
 
1.2.5.2.7 Chitosan 
Chitosan, a derivative of chitin, is obtained by the partial deacetylation of chitin. Chitosan 
comprises a series of polymers varying in their degree of deacetylation, molecular weight, 
viscosity, pKa etc. It has been widely used in wound dressing [99], controlled release of 
drugs [100-102], nerve regeneration [103], disc regeneration [104],  bone tissue 
engineering [105], cartilage tissue engineering [106-108] and skin tissue engineering 
[109]. Chitosan fiber could be made by wet-spinning process, but no mechanical 
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Hyaluronan (HA), also known as hyaluronic acid, is a polysaccharide of the extra cellular 
matrix (ECM). As a glycosaminoglycan (GAG), it has many structural, rheological, 
physiological and biological functions in the body, and is well distributed in various soft 
tissues [63]. Hyaluronan forms highly viscous solutions in water and interacts with 
binding proteins, proteoglycans and growth factors, while actively contributing to the 
regulation of the water balance, acting on the osmotic pressure and low resistance and 
selectively sieving the diffusion of plasma and matrix proteins. Due to its good 
biocompatibility and controlled biodegradability [80], hyaluronan has been used in joint 
surgery, corneal transplantation, cataract treatment, wound healing and angiogenesis. It 
has been well used in cartilage tissue engineering [111, 112], osteochondral defects repair 
[113] and cell-carrying medium [114]. However, water solubility and rapid in vivo 
degradation are disadvantages in making HA a potential material for ligament tissue 
engineering. Though several attempts have been made to fabricate a scaffold material with 
sufficient physical properties by cross-linking and coupling reactions, potential toxicity of 
some cross-linking agents, including gluteraldehyde, formaldehyde and isocyanates, 
continues to restrict its usage [63].  
 
1.2.5.3 Synthetic polymer  
For non-naturals, polymers in the group of polyesters, the family of polylactic acid (PLA), 
polyglycolic acid (PGA), polycaprolactone (PCL) and copolymers of lactic and glycolic 
acids (PLGA) could fulfill the criteria mentioned earlier to certain extent, including 
biocompatibility, processibility and controlled degradation [29]. Synthetic polymers also 
offer several advantages over natural polymers. Their chemical and physical properties, 
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including scaffold shape and porosity, degradation rate, cell adhesion ability and 
mechanical properties are easily modified by the processing and chemical modification. It 
leads to broad usages in recent tissue engineering [115].  
 
1.2.5.3.1 Poly-glycolic acid (PGA) 
PGA is highly crystalline, hydrophilic, linear aliphatic polyester with a high melting point 
(210ºC at a molecular weight of 50,000) and a relatively low solubility in most common 
organic solvents [116]. PGA degrades through hydrolysis and the degradation rate of PGA 
depends on the crystallinity, which is usually between 46-52% [117]. It usually loses most 
of its mechanical strength over the first 2-4 weeks of degradation in a fluid with pH 7, at 
37ºC in vitro [118]. Though there are a lot of reports on application of PGA in tissue 
engineering [119, 120], it has seldom been used directly in vivo due to limitation such as 
mechanical strength and quick degradation. It was usually used either as a scaffold for in 
vitro 3-D cell culture before implantation [120], or used as a template for further 
modification [121].  
 
1.2.5.3.2 Poly-lactic acid (PLA) 
PLA is also a polyester and is more hydrophobic and amorphous than PGA, with an 
increased solubility to organic solvents compared to PGA [116]. Due to an extra methyl 
group compared with PGA, PLA usually has two isoform, L- and D- forms, while L-form 
PLA, also known as PLLA, is most often found. PLLA has a lower melting point than 
PGA (159ºC at a molecular weight of 100,000). It degrades into lactic acid by de-
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esterification and degrades completely within a period of between 10 months to 4 years 
depending on its molecular weight, crystallinity, shape and implantation site [116, 119]. 
PLA has been widely used in cartilage tissue engineering [122, 123], bone tissue 
engineering [124], controlled release of growth factors [125], as well as ligament 
reconstruction [37, 126]. Due to its mechanical properties, it has also been used in 
combination with other polymers, as reinforcement or as modification reagent for other 
polymers [127, 128]. 
 
1.2.5.3.3 Poly-caprolactone (PCL) 
Polycaprolactone is a biodegradable thermoplastic polymer derived from the chemical 
synthesis of crude oil. As a semicrystalline polymer, its crystallinity tends to decrease with 
increasing molecular weight. Its high solubility in organic solvents, low melting point (59-
64ºC), slow degradation rate and exceptional ability to formulate blends have lead to 
many biomedical applications, such as drug delivery [129], cartilage tissue engineering 
[130, 131] and bone tissue engineering [132, 133]. PCL sutures were reported to keep 
90% of original strength after 18 weeks’ implantation [134]. It has also been used in 
fabrication of potential ACL prosthesis [135]. Unfortunately, there is no subsequent report 
on in vivo experiments.  
 
1.2.5.3.4 Co-polymers 
Copolymer is a polymer consisting of two or more different monomers. Copolymers of 
polyesters are currently often used in tissue engineering, such as PLGA (copolymer of 
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PGA and PLA at different ratios), tricalcium phosphate and poly (l-lactide-co-glycolide-
co -caprolactone) composites [133], poly(epsilon-caprolactone)-silica sol-gels [136] and 
hydroxyapatite/poly(epsilon-caprolactone) composite [137] for bone tissue engineering, 
since advantages or properties from different polymers could be effectively combined to 
achieve the specially designed purposes. Sometimes, surface modification of one polymer 
with another polymer could be done to achieve a special aim, to improve mechanical 
properties,  or to improve cell adherence [138-140]. 
 
1.2.5.4  Biocompatibility and Degradation  
Biocompatibility, defined as “acceptance of an artificial implant by the surrounding 
biological tissue and by the body as a whole” [141], is an important factor for all 
implantable biomaterials. In vitro characterization of materials and the functional 
performance of prototypes are usually prerequisites that must be met successfully, prior to 
evaluation of their biocompatibility [142]. Though PLLA and PGLA have long been 
regarded as biocompatible biomaterials, the knitted scaffolds made of these biomaterials 
have to be tested again due to potential contamination during fiber production and knitting 
procedure. 
 
Controlled degradation of biomaterials in tissue engineered constructs is important and 
difficult to achieve. An ideal tissue engineered composite should maintain a stable 
mechanical strength matching the original target tissue while degrading.  In other words,   
increased mechanical strength from regenerated tissue should make up the loss of 
mechanical strength caused by degradation of biomaterials (Fig 3) [61]. Though there is 
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more knowledge about degradation mechanisms of different biomaterials, most of them 
are based on in vitro degradation or in vivo muscle implantation.  From our experience, 
even the same material undergoes different degradation rates when implanted in knee 
joints, bone tunnels or onto periosteums. In addition, differences in composition, 
molecular weight, crystallinity, mechanical stimulus and processing of biomaterials will 
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Figure 3 Degradation of polymer 
Graphical illustration of the complex interdependence of molecular weight loss and mass 
loss of a 3D scaffold matrix plotted against the time frame for tissue engineering a 
cartilage/bone transplant [61]. 
(A) Fabrication of bioresorbable scaffold;  
(B) Seeding of the osteoblast/cartilage populations into the polymeric scaffold in a static 
culture (petri dish);  
(C) growth of premature tissue in a dynamic environment (spinner flask);  
(D) growth of mature tissue in a physiologic environment (bioreactor); 
(E) surgical transplantation;  
(F) tissue-engineered transplant assimilation/remodeling.  
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1.2.5.5 Cell- surface interactions 
As both cells and materials are essential components in ligament tissue engineering, the 
interactions between them are important. Materials could affect cell adhesion, 
proliferation and differentiation [127, 140] while cell adhesion and subsequent 
functionality also affect properties of surrounding materials. The cells include potential 
seeding cells, regenerative cells as well as inflammatory cells, such as macrophages, 
lymphocytes, neutrophils, etc. As ligament fibroblasts and their precursors have to attach 
before being functional, cell attachment is an important stage. Usually cells adhere to the 
material surface either by direct adhesion or by pre-absorbed proteins [143].   
 
In direct adhesion, cells first attach to a surface by pseudopodial extensions and then form 
focal contacts while they probe the surface for protein ligands [144]. The physical 
properties of cell adhesion are governed by both non-specific and specific interactions. 
Specific interactions refer to receptor-ligand bond formation, while non-specific 
interactions include electrostatic forces, steric stabilization and Van Der Waal’s forces. 
According to the fluid-mosaic model, the surface of an animal cell comprises a lipid 
bilayer composed of phospholipids, cholesterol and glycolipids [145]. Four major 
superfamilies of adhesion receptors have been identified in animal cells, including 
integrins, cadherins, immunoglobulins and the selectins. Among them, integrins are the 
most well studied and play an important role in cell-material interactions. Many integrin 
receptors recognize the specific peptide sequence Arg-gly-Asp (RGD), which is present in 
many adhesive proteins such as fibronectin, fibrinogen and vitronectin [146]. As 
transmembrane proteins, integrins are found to be involved in adhesion by linking 
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extracellular matrix proteins to the cytoskeleton. RGD peptide sequences have been 
immobilized onto synthetic surfaces to promote cell adhesion in a similar manner to 
fibronectin [147]. Some factors also affect cell adhesion, especially non-specific 
interactions, including temperature, medium concentration, small ion concentration and 
pH value of the surrounding medium, etc.  
 
On the other hand, cells also attach to materials through proteins which have been 
absorbed to material surface. Proteins contain regions of differing polarity, charge and 
hydrophilicity. The precise structures are not only determined by the specific amino acid 
sequence, but also by the secondary and tertiary structure that determines the 
conformation of the molecule, the distribution and orientation of the side groups. When a 
protein solution comes in contact with another phase, there is a tendency for the protein 
molecules to accumulate at the interface [143]. As nearly all interactions between 
mammalian cells and artificial surfaces are mediated by a layer of adsorbed protein [148], 
many proteins have been coated on surfaces of target materials when adhesion or 
improved biocompatibility is expected, for examples, fibrinogen [149], collagen [150], 
hyaluronan [151, 152], etc.  
 
1.2.5.6 Structures 
As we know that the ACL is a load-bearing tissue, which plays an important role in 
providing stability during the movement of the joints, e.g. extension and flexion. From a 
mechanical point of view, the ACL is an anisotropic structure which mainly bears the 
extension force in its axial direction. To restore ACL function, the ACL reconstruction 
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should functionally mimic all the characteristics of a normal ACL in terms of strength, 
compliance, elasticity, and durability without any side effects. Therefore, the mechanical 
properties of the ACL scaffold are of critical importance during regeneration or 
remodeling.  
 
Anatomically, the ACL is comprised of bands of dense collagen fibers. A fiber is a simple 
element of anisotropic structure. All the ACL scaffolds and synthetic prostheses are 
practically composed of fibers. The differences are the way to organize the fibers, i.e. their 
textile structures. Parallel structure is the simplest way to organize the fibers. However, 
the lack of interaction between fibers restricts its application. Twisting fiber bundles is an 
elegant way to solve the problem [26]. Twisting grafts are morphologically closer copies 
of the normal ACL and can eventually reduce and fine-tune the peak forces in extension 
[153]. Due the complexity of the ACL mechanical environment, researchers are keen to 
adopt more complex textile structures in ACL reconstruction, including all four textile 
categories: woven, non-woven, knitted and braided.  
 
The properties of textile grafts depend on the characteristics of the constituent yarns or 
fibers and on the geometry of the formed structure. In general, grafts that are braided are 
usually dimensionally very stable, but less extensible and porous than the other structures. 
A good example is the Gore-Tex ligament prosthesis composed of braided bundles of 
polytetrafluroethylene (PTFE) [27]. This graft has high strength and fatigue life, but 
limited tissue ingrowth due to the low porosity [3]. However, the pore size of the braided 
structures can be regulated by yarn bundle size and braiding angles [154]. Compared with 
 
--------------------------------------------- Introduction-------------------------------------------  
                                                                                                                                  
 
 
                                                                                                                                           34 
                                                                                                                                             
                                                                                                                                         
                                                                                                                                                 
braided fabrics, knitted structures are highly porous, which supports tissue ingrowth. It has 
been reported that the Dacron’s knitted construction promotes good ingrowth of fibrous 
tissue [155]. Textile materials for tissue engineering applications typically have specific 
performance requirements relating to porosity and mechanical properties.  
 
Porosity 
It is known that a highly porous scaffold is desirable to allow cell seeding or migration 
throughout the materials. Pore size is important for tissue ingrowth and determines the 
internal surface area available for cell attachment. A large surface area is required so that 
a large number of cells, sufficient to replace or restore organ function, can be cultured 
[156]. The fabric structures are hierarchically opened porous structures. Their pore 
porosities can be considered from three aspects [157]. One is the open space inside created 
by the loops for a knitted fabric or the pores between yarns in other fabric structures, 
which may range from tens to hundreds of microns. The other is the distance between 
filaments or fibers, which is about a few microns. A third kind of porosity can be induced 
by the method of assembling the fabrics by folding, rolling, etc.  
 
Mechanical properties 
The mechanical properties of the scaffold are often of critical importance especially when 
regenerating tissues such as ligament, tendon, cartilage and bone. The ideal artificial ACL 
perfectly mimics all the characteristics of a normal ACL in terms of strength, compliance, 
elasticity, and durability without any side effects. Unfortunately, none of the synthetic 
grafts have met the qualifications needed for a lasting ACL substitute (Table 3). Usually, 
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synthetic grafts are too rigid and begin to fragment gradually due to repeated cycling of 
the knee and probably some chafing at the edges of the bone tunnels, which leads to 
particles of prosthetic materials shedding and distributing throughout the joints, even 
occasionally spreading into the lymphatic system. 
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Table 3 Properties of textile structures 
 
 
Regardless of their initial mechanical properties, a loss of them occurs after 
transplantation due to the processes of ischemic necrosis and remodeling. Strength and 
stiffness of the grafts are also lowered by adding fixation [25]. 
 
If the stiffness of the implant greatly exceeds that of the ingrown host tissue, the implant 
will bear most of the mechanical load and the load-deprived host tissue will not remodel 




Composition[158] Yarn Yarn Yarn Fiber 












Mobility [158] Limited Tremendous Limited Very slight 
Porosity High Very high High High 
Examples Leeds-Keio PET 
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(LAD) is needed to protect biological grafts from high loads in the early postoperative 
period, in addition to being used as a permanent prostheses [170]. The Kennedy LAD was 
a braided polypropylene yarn attached to bone on only one end of the autogenous repair. 
Due to the low stiffness of the device, stress-shielding of the graft is reduced, thus normal 
neoligament remodeling should occur [27]. However, long-term maintenance of the 
mechanical properties of the device is not necessary or even desirable. Therefore, an ideal 
ligament augmentation device should be biodegradable, gradually transferring mechanical 
loads completely to the biological graft. The tissue engineering approach provides 
optimism by using biodegradable scaffolds combined with appropriate cell sources to 
create mechanically and biologically functional substitutes. In contrast to the permanent 
synthetic prostheses losing strength with time, the mechanical behavior of the tissue 
engineering grafts should improve with time due to neoligament tissue development and 
remodeling [27]. 
 
1.2.6 Regeneration and functionalilty 
As dense and well organized connective tissue, ligament attributes much of its function to 
its specific structures, cross-linked collagen bundles and crimps [12]. Though there are no 
unique cell markers for ACL, it still can be evaluated and distinguished by its specific 
expression of different factors and their relative ratios [3],  
• Specific expression of extracellular matrix components of collagen types I, III, V 
and their ratios, for example, collagen amount: 80.3mg collagen/g dry tissue and  
ratio of  collagen types I and III, 7.3 (both lower than tendon) [171] 
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• Different type and  higher amount of reducible cross-links compared with MCL 
and tendon [172]  
• Different cell morphology and function with distinct regions [171]  
• Special ultrastructure of collagen network (collagen pattern, collagen fibril 
diameter) [172] 
• Higher metabolical rate than tendons [171]  
• Specific expression of ground substances, elastin, fibronectin, decorin, and 
biglycan,  
• Specific expression of glycoaminoglycans (GAG), such as hyaluronic acid, 
chondroitin sulfate [172] 
• Furthermore, the composition of individual component changes in regeneration, 
while some of them promote functionality and the others may not or impede it 
[173].  
 
All these characteristics could give clues for future scaffolds for ligament tissue 
engineering.  
 
As degradation of scaffolds is inevitable, it is important to promote rapid functionality of 
regenerated collagen fibers. Except for seeding cells, enhancing the growth factors which 
have been implicated in regeneration, have all shown promise [174]. Blocking decorin 
formation by antisense gene therapy could increase diameter and maximal tensile strength 
of regenerated ligament [173]. Blocking Collagen V formation may have a similar 
positive effect [175]. Scaffolds carrying antisense gene therapy could be helpful.  
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Collagen fibers and “crimp-like structures” with different maturities have been reported 
after ACL reconstruction with tissue engineered ligaments, for examples, from 
carbodiimide but not glutaraldehyde cross-linked collagen fibers after 20 weeks [128], 
from hexamethylenediisocyanate (HMDIC) cross-linked collagen after 3 months [176], so 
far the relatively most matured collagen fibers from demineralized bone [35], and from 
fascia lata wrapped braided PLLA yarns after 48 weeks [177]. However, the 
unsatisfactory mechanical results showed that the regenerated collagen were unable to 
demonstrate original mechanical properties. Three reasons could be attributed to it; 1) the 
reported relatively mature and well orientated collagen fibers reside only in some areas of 
the grafts, but not homogenously; 2) they were only immature collagen with small 
diameters; 3) collagen fibers were not well oriented and lacked cross-linkages. 
 
1.2.7 Bioreactors 
There are three main strategies to engineer tissues clinically and scientifically, (a) direct 
cells to form specialized tissues, (b) provide and characterize the specific regulatory 
signals (biochemical, physical) that are known to modulate cell function and tissue 
development, (c) precisely control the environmental conditions (e.g.  pH value, 
temperature) and mass transport of chemical components (e.g. nutrients, oxygen, 
metabolites, growth factors) to and from the cells. Bioreactors are essential to meet these 
requirements and to further study the exact role of each factor [3]. Currently tissue 
engineering depends on two approaches to succeed: one is to implant  tissue engineered 
constructs directly into the injured sites to use an in vivo environment as “bioreactors”; or 
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to culture the constructs in vitro under well controlled conditions to promote tissue 
regeneration [178]. Sometimes, it is necessary to combine the two ways. Potential tissue 
engineered ACLs would not only face harsh environments, such as complex mechanical 
and enzymatic attacks, but also lack of blood supply at the initial stage. All these factors 
contribute to usage of bioreactors before in vivo implantations.  
 
While knowledge about embryo development and adult regeneration develops, bioreactors 
could employ more controlled conditions to fabricate desired tissues. Much attention has 
recently been focused on the development of bioreactors. Though many results support the 
notion that bioreactors providing dynamic loading are essential for meeting the complex 
requirements of in vitro engineering of functional skeletal tissues [3, 179], few of them 
has been specially designed for ligament  tissue engineering. Ligament-like tissue have 
been made in bioreactors [180, 181] in some general bioreactors, as well as in ligament 
designed bioreactors [76]. However, all of them could not induce mature collagen cross-
link and bundle formation, which symbolize the functional ligaments.  
 
1.2.8 Regulatory factors and controlled release 
Lots of biochemical factors, including growth factors, could promote or disturb tissue 
regeneration. Oxygen can markedly affect extracellular matrix (ECM) synthesis rates and 
the in vitro development of engineered tissues [182-184]. High oxygen tensions (21%) 
supported optimal ACL fibroblast proliferation, whereas lower tensions (10%) enhanced 
ECM collagen synthesis [185]. Ascorbate-2-phosphate (a long-acting derivative of 
vitamin C) could enhance cell growth and collagen excretion [186, 187]. Growth factors 
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are polypeptides that transmit signals to modulate cellular activities, stimulate or inhibit 
cellular proliferation, differentiation, migration and gene expression [188]. A lot of 
growth factors have the capacity to increase cell proliferation, including epidermal growth 
factor (EGF), platelet-derived growth factor (PDGF), basic fibroblast growth factor 
(bFGF), insulin-like growth factor II (IGF-II) and transforming growth factor-beta (TGF-β) 
[189-195]. Insulin, TGF- β, and IGF-II promote protein expression and ECM generation 
in soft connective tissue [192, 193, 196]. TGF- β and EGF (or insulin) act in concert to 
stimulate normal proliferation of fibroblasts and mesenchymal cells [193, 197, 198]. 
PDGF, FGF, cartilage-derived morphogenetic protein (CDMP) and growth and 
differentiation factor (GDF) also could promote functionalities in tendon and ligament 
regeneration [199-202]. Bone morphologic protein (BMP)-12 has also been reported to 
promote proliferation and collagen  expression of tendon fibroblasts in vitro and 
functionality in vivo  [203, 204]. 
 
The main concerns to use growth factors are cost and controlled release. As mentioned 
earlier in the section on bioreactors, tissue engineering may have to culture its products in 
vitro or in vivo, and sometimes both.  Growth factors could be incorporated into the 
scaffold either during or after scaffold fabrication [205-207] (or added when cultured in 
vitro sometimes), as well as be co-transplanted through natural growth factor-secreting 
cells or genetically engineered cells within the tissue engineering constructs [208].  Two 
hurdles currently hamper clinical usages of growth factors:  firstly, the exact role as well 
as necessary dose and duration of a growth factor have not been fully understood; 
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secondly, the technical profile for individual growth factor has not been fully established, 
though much progress has been made.  
 
1 .3  Animal model  
 
The use of animals in orthopedic research has played a vital role in the numerous medical 
advances, though public controversy regarding animal experimentation still exists. Most 
people however support animal experimentation, emphasizing the need to pay particular 
attention to animal welfare and animal rights [209]. 
 
1.3.1 Experimental design, evaluation and data analysis 
Each experiment is designed to answer one hypothesis, an unproven theory as well as a 
specific, logical and scientific form of a thought. After serious review on previous studies, 
an experimental design including number of animals used, consideration of animal 
variance, evaluation methods, randomization and sampling error and controls should be 
well stated [210].  The most often used evaluation methods in orthopaedic animal research 
are: clinical observation, radiography, macro-observation at necropsy, histological 
evaluation, and mechanical testing. Sometimes, electron microscopy, computed 
tomography (CT) and magnetic resonance imaging (MRI) are used. Data analysis is often 
necessary for a conclusion, which includes descriptive statistics, one-way sample analysis, 
paired/unpaired comparisons, analysis of variance, correlation and regression analysis and 
nonparametric data [210]. 
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1.3.2 Animal model of ligament 
As animal research acts as the bridge between in vitro studies and human clinical trials, 
the ideal way is to choose primate models, as the results from them are easily extrapolated 
to human conditions. However, when ethics, availability, housing requirements, ease of 
handling, costs as well as susceptibility to disease are considered as a group, the choices 
of animal species are usually compromised [211]. 
 
To investigate ligament regeneration and reconstruction, it is prudent to choose animal 
models in which the type and degree of ligament injury is similar to that in humans, and to 
realize that the results from animal research may be species and ligament specific and may 
not necessarily simulate that of humans [64]. Most often used animal models in ligament 
research are dogs, rabbits, goats and sheep. The reasons to use dogs are due to ease in 
handling, receptiveness to various exercise regimens as well as well published information 
[64]. Goats and sheep are broadly used for ACL reconstruction using biological grafts and 
ligament prostheses [212, 213] because of larger knee joint size and less degree of flexion. 
Rabbits are widely used in biomedical research due to their docile nature and relatively 
inexpensive purchasing cost and maintenance as well as well-documented biochemical 
and functional properties of rabbit knee ligaments [64].  However, their rather small joint 
size limits accuracy of ACL operations and obesity during long-term caging leads to high 
loads in the knee joints [64]. After the consideration of all these factors, the rabbit model 
was chosen to evaluate the performance of our knitted scaffolds for ACL reconstruction. 
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1 .4  Hypothesis & objective ACL  
 
The hypotheses of this study are as follows:  
a. knitted biphasic scaffolds can provide enough mechanical strength before ligament 
regeneration; 
b. mesenchymal stem cells (MSC) and fascia wrap can promote anterior cruciate 
ligament repair when used on knitted biphasic scaffolds followed by implantation 
in the knee joint. 
In view of these two hypotheses, the specific objectives of this project are designed as 
such: 
1. to select optimal cell source for ACL tissue engineering regarding proliferation, 
collagen excretion and collagen expression profiles. 
2. to design and characterize the knitted scaffolds for ACL tissue engineering on their 
mechanical properties and degradation. 
3. to test in vivo effects of knitted scaffolds used in a rabbit ACL reconstruction 
model, as well as MSC loading and fascia wrap. 
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2 Materials and Methods 
 
2.1 Cell selection 
2.1.1 Harvest and Culture of ACL fibroblasts, MCL fibroblasts and MSC 
All the animal experiments have been ethically approved by the Animal Holding Unit, 
National University of Singapore. In this study, 12 male NZW rabbits weighing between 
2.2-2.5kg were used. The ACL and MCL were harvested from the rabbits under sterile 
conditions according to the method described by Kobayashi et al [214] and Nagineni et al 
[215]. The anesthesia technique used was as follows: 0.3ml/kg hyponym was 
administrated intra-muscularly to tranquilize the animal; this was followed by intra-
venous 0.3ml/kg Valium for induction. Then, 1% halothane inhalation was used for 
maintenance. 0.3ml/per animal of cephacexin was given subcutaneously as antibiotics. 
Briefly, after the femoral and tibial insertions of the ligaments were resected, the synovial 
sheath and periligamentous tissue were stripped away from each ligament. Immediately 
following the isolation of the ACL and MCL, each ligament was carefully cut into 
1mm×1mm indices and digested with 5ml 0.25% collagenase (Gibco) in 37ºC shaking 
water bath for 10 hours followed by twice DMEM rinse. The isolated ligament cells from 
the two ACL of the same rabbit were cultured in one 25cm2 flask (Corning) with DMEM 
(Sigma, pH 7.4) supplemented with 10% FBS (GIBCO, 10270-106), 10,000U/ml 
penicillin/10,000μl/ml streptomycin and 2mM L-Glutamine (Gibco). Then the cell-
medium system was incubated at 37ºC with 5% CO2 until 80% confluence. It is important 
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The MSCs were isolated by using the short-term adherence to plastic method as described 
by Friedenstein [53]. Briefly, the procedure is as follows: the rabbit was put under general 
anesthesia and 2-ml of bone marrow was aspirated from iliac crest (Fig 4) and subjected to 
centrifugation. After centrifugation and wash, the cells were cultured in DMEM (Sigma, 
ph 7.4) supplemented with 10% FBS (GIBCO, 10270-106), 10,000U/ml 
penicillin/10,000μl/ml streptomycin and 2mM L-Glutamine (Gibco). The cells were 
cultured in 75cm2 flask (Corning) at 37º with 5% CO2 until 80% confluence. The medium 
was changed at every three-day’s interval. Hemopoietic cells were removed at each 
change of medium. Subsequently, the cells were trypsinized with 1ml of 0.25% trypsin-
EDTA (Gibco) and sub-cultured before use in the evaluation protocol and follow-up 
experiments. 
 
Figure 4 Aspiration of bone marrow 
 
2.1.2 Proliferation Assay 
Cell proliferation assessment of the three cell types, ie ACL fibroblasts, MCL 
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fibroblasts and MSC were performed after passage 1, with an initial cell number of 0.2 
million of each cell type.  The cells were cultured in 5ml of DMEM medium (with the 
same supplement as described previously) in a 25cm2 flask until 80% confluence. Once 
reached, the cells were trypsinized and counted again. The cell doubling times (TD) were 
calculated from the following equation: 
 TD=t·lg2/ (lgNt-lgN0) --------------------------------Equation 1 
where N0 and Nt are the primary cell number and acquired cell number respectively [216].  
 
2.1.3 Collagen Assay 
In order to carry out the collagen assay, 50,000 cells of each cell types were loaded in one 
of the wells of a 24-well plate. After 24hrs, the medium was changed to 0.8ml of DMEM 
supplemented with 5% FBS, 10,000U/ml penicillin/10,000μl/ml streptomycin and 2mM 
L-Glutamine (Gibco). Collagen assays were performed strictly according to the Sircol 
collagen assay kit protocol (Biocolor, UK). Briefly, the collected supernatant from the 
culture well was centrifuged at 1,500rpm for 4 min to drop the extracellular matrix (ECM), 
this was followed by mixing 100μl supernatant with 1ml of Sircol dye for 30 min and 
centrifuging at 10,000rpm for 5min to drop the formed collagen-dye complex. After 
decanting the suspension, droplets were dissolved in 1ml Sircol alkali reagent and 
vortexed. Subsequently, 100μl of the acquired solution was read at 540nm.  
 
2.1.4 Immunohistochemistry 
The immunohistochemistry evaluation was carried out on the three cell types; 10,000 
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cells of each cell types were cultured on each well of the 4-well chamber slide (Iwaki, 
Japan). The four wells were stained respectively with antibodies of monoclonal anti-
collagen type I (Sigma, C2456), monoclonal anti-collagen type II (Ab-3, NeoMarkers), 
monoclonal anti-collagen type III (63172, Chemical Credential, USA) and monoclonal 
anti-α smooth muscle actin (1A4, Sigma, A2547). The UltraVision Detection system (TP-
015-HD, Lab Vision Corporation) was used in this study. Pre-dilution of type I, type II 
and type III antibody was 1:4,000 while α smooth muscle actin antibody was diluted with 
1:400.  A brief description of the procedure is as follows: after one week of cell culture, 
the cells were fixed in 2% paraformaldehyde for 10min. The cells were then incubated 
with six drops of hydrogen peroxide and block for 15min, followed by Ultra V Block for 5 
min. Then, the cells were stained with the prepared primary antibody for 3 hour, 
biotinylated Goat anti-polyvalent for 10min, streptavidin peroxidase for 10min and finally 
with the freshly prepared DAB solution for 10min. The cells were washed before each 
step with PBS.  
 
2.2 Characterization of knitted scaffolds 
2.2.1 Fabrication of Scaffold  
The scaffolds were knitted out of two poly-L-lactic acid (PLLA) yarns (multifilament, 
nonbraided, 30 filaments, each filament between 15-20 microns in diameter, denier, 83, 
Scaffix International, USA, Fig 5) and 1 poly-lactic and glycolic acid (PLGA, the ratio of 
PLA and PGA in the co-polymer is 10:9, 12 filaments in one yarn and each filament 
between 15-35um in diameter, denier 50-60, Shanghai Tianqing Biomaterial, China, 
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Fig 6) in knitting machine (SK270, Silver Reed, Suzhou Harisa Machinery Co., China, 
Fig 7) with four-needle mode. The two ends of each 5cm long knitted structure were 
sealed with heat. In order to sterilize the scaffolds, they were immersed in 70% alcohol for 
30min after being washed with PBS twice. Subsequently, the scaffolds were immersed in 
3 changes of PBS for 15min before use. 
 
 
Figure 5 PLLA yarn (white) 
   
Figure 6 PLGA yarn (blue) 
 
  
   50                              
 
-------------------------------------MATERIALS AND METHODS ----------------------------- 
 
                                  
 
 
Figure 7 Knitting machine 
 
2.2.2 Tetrazolium-based colorimetric assay (MTT) 
The test scaffolds were cut into 5mm long strips and sterilized by above mentioned 
methods. One well of 96-well plate was filled with 100μl of 5×105cell/ml of cell 
suspension. The test scaffolds, as well as positive controls (rubbers) and negative controls 
(high density polyethylene, 54670, USP, US) were placed in the wells (4 replicates) while 
another 4 wells were maintained free of sample as control. The system was incubated at 
37°C, 5% CO2 and the percentage of viable cells was determined after 24 hrs. Twenty 
microliters of MTT solution (5mg/ml) was added in each well and after 3h of incubation 
at 37°C, 5% CO2 the wells were emptied and 150μl of DMSO was added to each well and 
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2.2.3 In vitro cell loading on scaffold  
Two centimeter long knitted scaffolds were folded back before two loose ends were sealed. 
After sterilizing with the above mentioned method, 2 million MSCs in 30μl tisseel were 
loaded onto scaffolds, followed by 30μl thrombin (Tisseel Kit, Baxter, Austria). After 
20min of incubation at 37°C, 5% CO2, 1ml of above mentioned DMEM was added to 
each well in 24-well plate containing the scaffold. Medium was changed at two-day 
intervals. Ten days later, scaffolds were incubated with 10ng/ml FDA (Fluorescein 
diacetate, F1303,molecular Probes, Oregon, USA) for 2 min just before being examined 
by Laser Scanning Confocol Microscope (TCSSP2, Leica, Germany) at 490nm. 
 
2.2.4 Characterization of the knitted structures 
2.2.4.1 Porosity 
The porosity of the knitted scaffolds was estimated by deduction of cross-section areas of 
individual PLLA yarns and PGLA yarns from gross cross-section of scaffolds. Knitted 
scaffolds, PLLA yarns and PGLA yarns were fixed under slight tension (approximately 
5N) before the diameter was measured under phase contrast microscope. The following 
formula was used to calculate the porosity of the scaffolds: 
 Porosity= 1-(PLLA area +PLGA area)/scaffold area 
PLLA area: the sum of all cross section areas of PLLA yarns  
PLGA area: the sum of all cross section areas of PLGA yarns  
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After immersion for scheduled time, the scaffolds were fixed in paraffin under little 
tension. Then the specimens were cut to 6μm with microtome, before cross-sections were 
examined under microscope (Olympus BX51) and counted with Olympus Microimage 
4.5.1. 
 
2.2.4.2 Molecular weight 
One microgram of samples was dissolved in 2ml chloroform (i.e. concentration of sample 
is around 0.05%)  before molecular weights were determined by Gel Permeation 
Chromatography (GPC, Waters, USA) at an elution rate of 1ml/min at 25°C with a 
column (Shodex K-806M, Japan). 100ul was analyzed each time while polystyrene was 
used as the standard. Mean values at each time points were compared with one way 
ANOVA (LSD, P<0.05).  
 
2.2.4.3 Mechanical properties of the scaffolds 
The two ends of the scaffolds were sandwiched between sand papers and secured by super 
glue (Alteco 110, Alteco Chemical, Singapore, Fig 8) to prevent slippage of the scaffolds 
between the pneumatic grips used in the tensile test. The scaffolds had a gauge length of 
20mm. The tensile properties were measured with the Instron 5848 Micro Tester at a 
constant strain rate of 0.8%/s (Fig 9). The cross-sectional area of the scaffold was taken to 
be the sum of cross-sectional areas of the individual filaments measured under an optical 
microscope. The values of stress were obtained by dividing the load by the cross-sectional 
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area of the scaffold. The strain values were obtained by dividing the elongation by the 
gauge length of the specimen. The first linear region (i.e. at lower strain levels) after “toe” 
region was used for determination of modulus. The percentage changes in gradients before 
and after every ten points were obtained. The region with the smallest fluctuation in 
percentage change was picked. From this selected region, a tangent line was drawn, which 
gradient gave Young’s Modulus. 
The viscoelastic properties were studied by carrying out relaxation and creep tests. In both 
viscoelastic tests, a pre-load of 0.2N was first applied before pre-conditioning the 
scaffolds for 10 cycles at a frequency of 0.1Hz and amplitude of 2% gauge length. The 
scaffolds were then stretched to 2.5% strain for relaxation tests and 1.5N load for creep 
test and held at the strain and load values respectively for 900s. The strain and load levels 
selected for the viscoelastic tests correspond to the range of strain experienced in vivo [20].  
The normalized stress relaxation rate is obtained by finding the slope of the normalized 
stress vs ln(t) strain plot. The normalized stress is obtained by dividing the stress values 
by the initial stress immediately after the initial 2.5% strain has been applied (i.e. stress at 
time zero). The logarithmic operation on the time axis transformed the inherently 
nonlinear relation in load decay vs time into a linear relation such that a simple linear 
regression could be used to determine the rates of relaxation [217].   
 
Similarly, the normalised creep rate is obtained using the same method. For creep test, the 
normalised strain is obtained by dividing the strain values by the initial strain immediately 
after the initial 1.5N load has been applied (i.e. strain at time zero). The logarithmic 
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operation of the time axis transformed the inherently nonlinear relation in strain vs time 
into a linear relation such that a simple linear regression could be used to determine the 
creep rates. 
 
Figure 8 Specimen preparation 
   
  
Figure 9 Instron 5548 microtester 
 
2.2.4.4 In vitro degradation  
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Knitted scaffolds were immersed in1ml of above mentioned DMEM in15ml centrifuge 
tubes. The systems were incubated at 37°C, 5% CO2 while medium was changed weekly. 
PH values from three centrifuge tubes were measured as a group by using a pH meter 
(Coring PH meter 430).  The scaffolds were immersed for 4, 8, 12, 16, and 20 weeks 
before weighing; GPC and mechanical tests were done according to previous methods. 9 
replicates were used at each time point (3 for mass loss followed by GPC and 5 for 
mechanical testing). After immersion for the scheduled time, the scaffolds were fixed in 
paraffin under little tension. Then the specimens were cut to 6μm with a microtome, 
before cross-sections were examined under the microscope (Olympus BX51) and counted 
with Olympus Microimage 4.5.1. 
 
2.3 ACL reconstruction in Rabbit Model 
2.3.1 Reconstruction 
Animal experiments were ethically approved by the Animal Holding Unit, National 
University of Singapore. Forty-eight skeletally-matured male New Zealand White rabbits 
weighing 3.0 - 3.4 kg were divided into four groups, with 12 rabbits in each group, while 
4 additional rabbits were used for cell survival test (Table 4). The anesthesia technique 
used was as follow: 0.3 mL/kg hyponym was administrated intra-muscularly to tranquilize 
the animal; this was followed by intra-venous 0.3 mL/kg Valium for induction. 
Subsequently, 1% halothane inhalation was used for maintenance. 0.3 mL/per animal of 
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Cells Fascia cover 
Group I 14 2 - - 
Group II 14 + 2 2 + - 
Group III 14 + 2 2 + + 
Group IV 14 2 - + 
 
The operations were performed under aseptic conditions. The right knee joint of the rabbit 
was exposed using a midline skin incision and lateral parapatellar arthrotomy. The patella 
was dislocated medially with the knee extended. With the knee placed in hyperflexion 
state, normal ACL was removed by sharp dissection at the tibial and femoral attachment 
sites, while the fat pad was left intact. Using a 2-mm diameter drill bit and a gas–driven 
drill (K 100 Air Powered Mini Driver, 3M, USA), bone tunnels were made from the 
anatomic ACL femur attachment site to lateral femoral condyle (Fig 10), as well as from 
the anatomic ACL tibial attachment site to medial tibia, which is distal and medial to the 
tibial tubercle. Each end of the sterile knitted scaffold was sutured with 4-0 Vicryl suture 
(Ethicon, NJ), to facilitate the ease of threading the scaffold through the tibial and femoral 
bone tunnels. For group I, two scaffolds were combined and passed through the femoral 
bone tunnel, into the intraarticular space, and through the tibial bone tunnel separately 
(normal procedure). For group II, 3 million MSCs in 60μl of Tisseel fibrin glue (Baxter 
Healthcare Corporation, Glendale, CA) were loaded on the two scaffolds before normal 
procedure. For group III, firstly, a 0.5 cm wide and 5 cm long fascia lata at lateral 
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part of femoral condyle was carefully dissected, while keeping the pedicle near the femur 
bone tunnel connected.  After 3 million MSCs in 60 μL of Tisseel fibrin glue were loaded 
(Fig 11), the scaffolds were wrapped with pedicle fascia lata (Fig 12) and sutured with 4-0 
Vicryl suture just before normal procedure.  For group IV, the scaffolds were wrapped and 
sutured with same fascia lata as in group III prior normal procedure. The two ends of the 
construct in each group were then sutured to the periosteum with 2-0 Ethibond non-
absorbed suture (Johnson &Johnson, USA). This was done with the knee at 45º of flexion 
with the constructs in slight tension. The experimental rabbits were left in cage without 
immobilization. After twenty weeks, the rabbits were euthanized by 1 mL (400mg) /2.5kg 
body weight of pentobabitone sodium (Euthanasia Fort Solution, Apex Laboratories, 
Australia) and knee joints were dissected for histology and mechanical test.  
 
 
Figure 10 Drilling bone tunnel at femur 
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Figure 11 Cell loading on the scaffold 
 
Figure 12 Fascia lata dissection 
 
2.3.2 Histology and Immunohistochemistry 
Two rabbits from each group were sacrificed at 4 weeks for histological study and the 
remainings were sacrificed at 20 weeks for histology, immunohistochemistry, western blot 
analysis and mechanical testing. All connective tissues and other ligaments in the knee 
joints were removed except for the ACL. For histology, the harvested specimens were 
immersed in 10% formalin for one week prior to decalcification in 30% formic acid for 
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For immunohistochemistry, the harvested ACLs were cryo-sectioned to 6μm and placed 
on Saline-PREPTM slides (s4651, Sigma Diagnostics, MO, USA) before fixation with 
acetone for 4 min. Slides were stained with anti-collagen type I (Sigma, C2456) and anti-
collagen type III monoclonal antibodies (63172, Chemical Credential, USA). The 
UltraVision TM Detection system (TP-015-HD, Lab Vision Corporation) was used in this 
study. Pre-dilution of type I and type III antibody was 1:2,000.  A brief description of the 
procedure is as follows: Slides with harvested specimens were incubated with hydrogen 
peroxide for 15min, followed by Ultra V Block for 5 min. Cells were then stained with the 
prepared primary antibody for 3 hour, followed by biotinylated goat anti-polyvalent for 10 
min, streptavidin peroxidase for 10 min and finally with freshly prepared DAB solution 
for 10 min. The slides were washed in between steps with PBS.  
 
2.3.3 Mechanical testing 
Five rabbits from each group were used for mechanical testing (tensile test) while five 
randomly chosen left knees were used as controls. The knee joints with intact capsules and 
4 cm of femurs and tibias were harvested. The specimens were sealed and kept in -80 ºC 
until they were tested. The specimens were thawed at room temperature for 24 hours and 
were dissected free of all connectives tissue and other ligaments except for the ACL. The 
knee joints of the specimens were covered with saline wet gauze to keep the samples 
moist at all times (Fig 13). The knees were mounted with Meliodent (CE 0044, Heraeus 
Kulzer GmbH, Germany) in the proximal femur and distal tibia, clamped at 45º 
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flexion in a Instron 5543 material testing system (Instron, Canton, MA)(Fig 14). Cross-
sectional areas were determined by assuming an elliptical cross-section and measuring the 
minor and major axes of the ligament midsubstance using Vernier calipers with minimal 
compressive force. The maximal load and elongation were measured at a constant speed 
of 2 cm/min. The specimens were sprayed with saline from time to time (Fig 15). Stiffness 
was determined by calculating the slope of the load versus displacement plot. The first 
linear region (i.e. at lower strain levels) after “toe” region was used for determination of 
stiffness. The percentage changes in gradients before and after every ten points were 
obtained. The region with the smallest fluctuation in percentage change was picked. From 
this selected region, a tangent line was drawn, which gradient gave Young’s Modulus. 
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Figure 14 Knee joint mounted in dental cement and fixed in Instron machine 
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2.3.4 Western blot 
ACL specimens after mechanical testing were used for western blot analysis. Ten pieces 
of 10μm slices were cut from each explant and extract in buffer (pH 6.8) consisting:  48% 
(w/v) high-purity urea (Gibco BRL, #15505-050), 15.2% (w/v) thiourea (Bio-Rad, highest 
purity), 0.075M dithiothreitol (Bio-Rad), 0.0498M Trizma base (Fluka, high purity), 3% 
(w/v) SDS (Bio-Rad) and 0.004% bromophenol blue. 
 
Calibration curve was made with Bio-Rad Protein Assay (Bio-Rad Laboratories, CA, 
USA) according to protocol. Briefly, 20mg of lyophilized bovine serum albumin (BSA) 
standard was reconstituted with 20ml of deionized water and mixed until totally solved. 1 
part Dye Reagent concentrate was diluted with 4 parts distilled deionized water before 
filtered with Whatman #1 filter to remove particulates. BSA standard was further diluted 
to different concentrations between 0-250μg/mL. 10μl of standard at different 
concentration was added into one of 96-well plate with 200μl diluted dye reagent solution.  
After totally mixing with microplate mixer and incubating for 10 min, absorbance was 
read at 595nm with SUNRISE microplate reader (TECAN, Au). Duplicate standard was 
examined.  
 
Equal amounts of total proteins (10ug) were loaded to 7% SDS-minigels at 15m Amps per 
gel until the marker dye reached the bottom of the gel. The protein was transferred to the 
nitrocellulose membrane by electrophoretic blotting from the gel using the Trans-blot 
Electrophoretic Transfer cell (Bio-Rad). The transfer was run overnight at 29V. The 
membrane was immersed in blocking solution (6% non-fat dry milk in TBS). The 
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solution was then placed on an orbital shaker for one hour at room temperature. The 
blocking solution was poured out and TTBS was added to wash the membrane. The 
membrane was washed for 5-10 minutes while gently agitating the solution at room 
temperature. After removing the TTBS, the primary antibody solution (Anti-collagen type 
I, human (mouse), Calbiochem) or (collagen type III, oncogene) prepared in 1% skimmed 
milk was add to the membrane and shaken for 1-2 hours at room temperature. The 
membrane was again washed in TTBS as described above. After repeating the wash cycle, 
the TTBS decanted and the second antibody, the horseradish peroxidase–conjugated anti-
mouse IgG Ab 6789 (Abcam Ltd) was added to the membrane. Once again, the membrane 
was incubated with gentle agitation for 1 hour at room temperature. The membrane was 
washed using TTBS as described previously, and repeated four times. At the same time 
the chemiluminescence reagent (Perkin-elmer) was prepared by mixing an equal volume 
of the enhanced Luminol Reagent and the Oxidizing Reagent and added to the membrane 
for 1 min. Exposion to Kodak X-OMAT was for 30 sec. Then the acquired results were 
scanned and analyzed with gel pro analyzer (MediaCybernetics) software.  
 
2.3.5 Cell survival-labeling-CFDA 
Four additional rabbits were used for cell survival tests.  Two of them were treated 
according to procedures in group II while group III rabbits respectively. Three million of 
P1 MSCs were stained with 15mM of VybrantTM CFDA SE Cell Tracer Kit (V-12883, 
Molecular Probes, Oregon) for 15 min and cultured for 24 hours prior to loading on 
scaffolds for ACL reconstruction, in group II (scaffolds plus cells) and group III 
(Scaffolds plus cells and fascia cover) . The cell-loaded constructs in the knee joints 
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were dissected and cryo-sectioned at 8 μm before examination under a confocal laser 
microscope (TCS SP2, Leica, Germany) at 488 nm. 
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3 Results and discussion 
 
3.1 Cell selection for ligament tissue engineering 
3.1.1 Cell Proliferation Study 
 
The ACL fibroblasts (Fig 16) and MCL fibroblasts (Fig 17) acquired from digestion were 
anchorage dependent and well distributed in the flasks, although they occasionally showed 
“clone-like” growth. They grew in monolayer and showed typical fibroblast-like 
morphology either with spindle shapes (bipolar) or stellate (multipolar) patterns. However, 
cell morphology varied a little between different areas and with the time of the culture. 
The total numbers of acquired cells were not stable from batch to batch, ranging from 
200,000 to 500,000 fibroblasts after 10-14 days’ culture with the current technique. It was 
also observed that some of the cells started to show senescence with fatty morphology.  
 
 
Figure 16 ACL fibroblasts (40x) 
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Figure 17 MCL fibroblasts (40x) 
 
One and a half million to three million MSCs were acquired with typical colony forming 
property and fibroblast-like morphology after 18-20 days of cell culture (Fig 18). They 
were also anchorage dependant and grew in monolayer. In general, they were larger than 
ACL and MCL fibroblasts and with visible nucleus and nucleolus. After the first passage 
(P1), it was observed that the MSCs kept the previous fibroblast-like morphology and 
proliferated well, but after the second passage (P2) at 25 days (Fig 19) as well as the third 
passage (P3) at 30days (Fig 20), the MSCs stopped proliferation while they increased in 
size and had irregular morphology. MSCs at P3 were even larger than MSCs at P2. The 
difference in size was obvious when MSCs were trypsinized. 
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Figure 18 Primary mesenchymal stem cells (MSCs, 40x) 
 
 
Figure 19 Passage 2 of MSCs (100x) 
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Figure 20 Passage 3 of MSCs (100x) 
 
From equation 1 (given in the preceding section), the MSC at P1 were estimated to double 
in number at an average of 55.6h (+14h, n=4) while the number of dead P1 MSC was too 
small to quantify. The total number of MSCs at P2 and P3 dropped after 44 hours in 
current culture condition, while some of them became detached and died. This was 
demonstrated by using trypan blue (Sigma, T8154, USA) (Table 5). As for the ACL and 
MCL fibroblasts, after the first passage, the cells stopped proliferating as a whole and 
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Table 5 Proliferation of MSCs 
 
 Cell No at 44h 
No. of dead 
cells at 44h 
Cell No. at 
168h 
No. of dead 
cells at 168h 
P1 MSC 362k +65.6k -- -- -- 
P2 MSC 160k +15.4k 20k +5.6k 92k +23.6k 13k +2.2k 
P3 MSC 134k +35.5k 18k +3.1k 97k +11k 15k +5k 
 
 
After 44h proliferation, the number of dead P1 MSC was too small to quantify. As for the 
ACL and MCL fibroblasts, after the first passage, the cells stopped proliferation as a 
whole and started to deteriorate with obvious morphological changes, i.e. increase in size 
and irregular shape formation. 
 
Proliferation, protein synthesis and deposition of extracellular matrix components have 
been shown to play crucial roles in the repair and remodeling of ligaments [218]. In 
addition, the survival of loading cells is crucial in tissue engineering experiments. It has 
been found that the rate of proliferation and collagen excretion of MSCs were higher than 
that of ACL and MCL fibroblasts, while all of them expressed collagen I, III and α-
smooth muscle actin, but not collagen II.  
 
MSC could be harvested from periosteum [219], muscle connective tissues [220] and 
adipose tissues [221], however, the most accessible and reliable source is the bone marrow. 
Since Friedenstein et al reported the initial isolation of bone marrow MSCs through 
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their adherence to tissue culture surfaces [53], the methods for MSC isolation have not 
been well developed. Several research groups have developed protocols to prepare more 
homogeneous populations [43, 55, 222], including the use of density gradients in an 
attempt to further separate sub-populations of adherent cells [223], but none of these 
protocols has gained wide acceptance. In this study, the most common protocol, ie direct 
plating [53] was used to culture the MSC due to the ease of the procedure and wide 
acceptance in most MSC related works. Phenotype of the acquired MSCs has been 
testified by their potential to differentiate into osteo-lineage, chondro-lineage and adipo-
lineage [224], as well as the typical well-spread morphology [43]. 
 
Previous studies had reported that sub-populations of human MSC could be amplified by 
about 20 to 120 population doublings [43, 45] and even up to one giga fold [44] in defined 
conditions before growth arrest and terminal differentiation was observed. However, to 
the authors’ knowledge no similar report has been made in rabbit MSC. One of the key 
factors in reduced number of mesenchymal progenitor cells in isolation and culture is age. 
This had been reported in both human [56] and rabbit [55] studies. Though rabbit MSC as 
a whole could not proliferate well after passage 2 (i.e. 25days) in current culture 
conditions, it was not necessary for all sub-populations to stop proliferation, especially 
when high variability existed in rabbit MSCs [225]. The proliferation rate of ACL and 
MCL fibroblasts were slightly lower than those reported in a previous study [215], 
possibly due to difference in age of rabbits.  
 
In considering the use of ACL fibroblasts, it is possible that after rupture, the stump 
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of the ACL could still possibly serve as potential cell source for further tissue engineering 
repair and regeneration, although inflammatory reactions may distort and impede the 
proliferation of fibroblasts [226]. The potential of MCL to heal without intervention [227, 
228] also makes the MCL a potential cell source for ACL repair and regeneration. In this 
study, it was found that the proliferation rate of ACL fibroblasts and MCL fibroblasts 
were slightly lower than those reported in previous studies [215]. In comparison between 
the proliferation rates of MSCs, the proliferation rates of ACL fibroblasts and MCL 
fibroblasts were much lower. The cultured ACL and MCL fibroblasts could not be 
expanded to large amounts and exhibited senescence after 14 days.  
 
3.1.2 Collagen assay 
       MSCs, ACL fibroblasts and MCL fibroblasts all actively excreted collagen. Collagen 
excretion of P1 MSCs and P2 MSCs were 37.1mg/ml and 36.4mg/ml respectively, which 
were higher than ACL fibroblasts (23.2mg/ml) and MCL fibroblasts (19.8mg/ml). There 
was no significant difference either between P1 and P2 MSC or between ACL fibroblasts 
and MCL fibroblasts, while collagen excretion of P1 MSCs and P2 MSCs are significantly 
higher than ACL and MCL fibroblasts [one-way ANOVA, LCD, p<0.05] (Fig 21 and Fig 
22) [One-way ANOVA, LSD, p<0.05] (Table 6). Since P2 MSCs had already stopped 
proliferation, therefore it was not necessary to measure P3 MSCs’ collagen excretion.   
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Table 6 Multiple comparisons of collagen excretion of MSCs, ACL and MCL fibroblasts 
95% Confidence Interval 




Std. Error Sig. 
Lower 
Bound Upper Bound
P2 MSC 0.76 1.64 0.65 -2.55 4.06 
ACL 13.94 1.78 0.00 10.37 17.51 P1 MSC (37.1mg/ml) 
MCL 17.30 2.09 0.00 13.11 21.49 
P1 MSC -0.76 1.64 0.65 -4.06 2.55 
ACL 13.18 1.94 0.00 9.29 17.08 P2 MSC (36.4mg/ml) 
MCL 16.54 2.23 0.00 12.07 21.01 
P1 MSC -13.94 1.78 0.00 -17.51 -10.37 
P2 MSC -13.18 1.94 0.00 -17.08 -9.29 ACL (23.2mg/ml) 
MCL 3.36 2.33 0.16 -1.31 8.03 
P1 MSC -17.30 2.09 0.00 -21.49 -13.11 
P2 MSC -16.54 2.23 0.00 -21.01 -12.07 MCL (19.8mg/ml) 
ACL -3.36 2.33 0.16 -8.03 1.31 
 
LSD, the mean difference is significant at the 0.05 level. 
 
Collagen is the most abundant protein in mammals, constituting 25% of the total protein 
mass [229]. The individual collagen polypeptide chains are synthesized on membrane-
bound ribosomes and injected into the lumen of the endoplasmic reticulum (ER) as larger 
precursors procollagen. After secretion of procollagen, the propeptides are removed by 
specific proteolytic enzymes outside the cell. This converts the procollagen molecules to 
collagen molecules, which assemble in the extracellular space to form much larger 
collagen fibrils. Procollagen is usually 1,000 fold more soluble that collagen molecules 
[229]. Though serial extraction of collagen have been used to examine the total collagen 
content in extracellular matrix [230], it is also reasonable to measure the level of collagen 
excretion ability of cells by determining the procollagen as reported [231, 232], as 
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procollagen propeptides and mature collagen are synthesized in a ratio of 1:1. It was 
observed that the level of collagen excretion of MSCs was more than 40% higher than that 
of ACL fibroblasts and MCL fibroblasts. Based on the results of the proliferation and 
collagen excretion studies, MSCs clearly exhibited distinct advantages over ACL 
fibroblasts and MCL fibroblasts, as a potential cell source for tissue engineering repair 




MSCs were positively stained with collagen type I, III and α-smooth muscle actin while 
negatively stained with collagen type II (Fig 23, 24, 25). The staining densities of collagen 
I and III for individual MSC varied while more than 90% of MSCs were well stained. The 
staining densities of alpha smooth muscle actin for individual MSC were more 
homogenous and well distributed in cytoplasma.  
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Figure 23 Collagen type I staining of MSCs (100x) 
 
 
Figure 24 Collagen type III staining of MSCs (100x) 
  
   76                              
------------------------------------ RESULTS AND DISCUSSION --------------------------------- 
 
 
Figure 25 Alpha smooth muscle action staining of MSCs (100x) 
 
Both ACL and MCL fibroblasts were positively stained with collagen I, III and α-smooth 
muscle actin while negatively stained with collagen II (Fig 26-31). The staining densities 
of collagen I for ACL and MCL fibroblasts were lower than MSCs while there was no 
difference in density among collagen I, III and α-smooth muscle actin.  The stained 
collagen I, III and α-smooth muscle actin were well distributed in the cytoplasma.  
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Figure 26 Collagen type I staining of ACL fibroblasts (100x) 
 
Figure 27 Collagen type III staining of ACL fibroblasts (100x) 
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Figure 28 Alpha smooth muscle actin of ACL fibroblasts (100x) 
 
Figure 29 Collagen type I staining of MCL fibroblasts (100x) 
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Figure 30 Collagen type III of MCL fibroblasts (100x) 
 
Figure 31 Alpha smooth muscle of MCL fibroblasts (100x) 
 
Various cells have been used in ligament tissue engineering and many of them have 
reported the fate of loaded cells in ACL reconstruction with tissue engineering methods 
[50, 233-235], but little has been discussed about the functionality of these cells. In 
previous studies, skin fibroblasts [236] has been identified as a potential candidate 
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for ligament tissue engineering primarily due to their abundance in the body. However, it 
may not be an appropriate choice for the following reasons: Firstly, harvesting of skin 
normally results in high morbidity. Secondly, the physiological environment of skin 
fibroblasts is distinctively different from that of the ACL, thus it may potentially affect 
their performance. 
 
Type I collagen is about 6 to 8 times more abundant than type III collagen in ligamentous 
tissues, while other collagens such as types V, VI and XII occur in small amount. 
However, there was no visible difference in staining density between collagen I and III in 
the fibroblasts and the MSCs.  A probable explanation for this phenomenon could be that 
the collagen III content was significantly increased during injury [237]. The quantitative 
ratio of collagen I to collagen III is important for the ultimate fibril diameter and 
functionality [238]. In the current study, the exact ratio was not determined and estimated 
less than its normal ratio. One potential concern is that the functionality of cells in 2D 
culture is different from 3D. However, we hope that our current study can provide a clue 
for better understanding.  
 
The results from the immunohistochemistry assessment showed that the MSCs, as well as 
both the ACL fibroblasts and MCL fibroblasts, excreted type I and type III collagen, 
however, the amount of collagen from MSCs was about 40% more than that from ACL 
fibroblasts and MCL fibroblasts.  
 
Fibroblasts play pivotal roles in connective tissue development, physiological 
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remodeling, and wound repair. These cells are likely to comprise heterogeneous 
populations [239]. Alpha-Smooth muscle actin is a functional marker for a fibroblast 
subtype (i.e. myofibroblast) that rapidly remodels the extracellular matrix [240]. 
Myofibroblasts containing α smooth muscle actin also play an important role in the 
healing process of rabbit medial collateral ligament [241] and maintaining human ACL 
[242]. Alpha-Smooth muscle actin also has been reported in rabbit, canine [243] and 
murine [244] MSC, but there is no report on rabbit ACL fibroblasts. As in vitro cell 
culture could increase α-smooth muscle actin expression [245, 246], there is still much to 
study in order to evaluate and quantify the content of α-smooth muscle actin expression in 
vivo as well as in tissue engineered ligaments.  
 
This study has shown that rabbit MSCs have clear and distinct advantages over ACL 
fibroblasts and MCL fibroblasts, with respect to proliferation and collagen excretion rates. 
The cultured rabbit MSC were found to share the same collagen expression-types and α-
smooth muscle actin as the ACL fibroblasts and MCL fibroblasts. Therefore, MSCs were 
shown to be a potentially a better cell source than ACL fibroblasts and MCL fibroblasts 
for tissue engineering repair and regeneration of ACL or any other ligamentous tissues. 
 
3.2 Characterization of knitted scaffolds 
3.2.1 Tetrazolium-based colorimetric assay (MTT) 
PLLA and PLGA yarns were knitted into flat sheets before rolling up into tube-like 
scaffolds. In the current study, four needles were used to knit. Theoretically, more 
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needles (Up to 100) could be used to knit different sizes of knitted sheet and there is no 
limited length for the fabricated scaffolds. Current 6-cm yarns were designed for the ACL 
reconstruction in rabbits’. The acquired knitted scaffolds were blue porous scaffolds (Fig 
32), while the porosity could decrease to some extent under slight tension (Fig 33).  
 
 
Figure 32 Knitted scaffolds 
 
 
Figure 33 Knitted scaffold under slight tension 
 
Current results showed that the knitted structures were free from contamination after 
sterilization (Fig 34), which was important for future tissue engineering applications. 
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The tetrazolium-based colorimetric assay (MTT) is a quantitative method for evaluating 
the biological response of cells to a foreign body in order to determine the sterility of the 
structures. Mesenchymal stem cells were used instead of characterized cell lines, which 
were more commonly used, because mesenchymal stem cells were a better loading cell 
source, compared to ACL fibroblasts and MCL fibroblasts in ligament tissue engineering 
with regards to proliferation rate and collagen excretion. Phenotypic characterization of 
acquired MSCs were confirmed based on their typical morphology, as well as osteogenic, 
















Figure 34 MTT results of the knitted structures 
 Sample: knitted structures, NC: negative control, PC: positive controls. 
 
Biocompatibility, defined as “acceptance of an artificial implant by the surrounding 
biological tissue and by the body as a whole” [141], is an important factor for all 
implantable biomaterials. In vitro characterization of materials and the functional 
performance of prototypes are fundamental prerequisites prior to evaluation of their 
biocompatibility [142]. PLLA and PGLA have long been regarded as biocompatible 
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biomaterials, however, the knitted scaffolds made from these biomaterials need to be 
tested again due to potential contamination from fiber production and scaffold fabrication. 
It is also critical to ensure that no contaminant resides within the scaffold that can 
potentially aggravate the culture environment, while the scaffold degrades and becomes 
less compact.  
 
3.2.2 In vitro cell loading on scaffold 
MSCs adhered readily to the knitted structures and appeared elongated (Fig 35). As fibrin 
gel is a natural product, using it in the cell loading process could mimic in vivo interaction.  
The relationship between biomaterials and surrounding cells is an important factor, both in 
vitro and in vivo. Microfilaments in the cytoplasm can be connected with the cell 
membrane via intergrin structures, which can also bind to the RGD sequence of 
fibronectin or other adhesive proteins. These adhesive proteins can in turn bind to solid 
substrates such as the extracellular matrix components and other cells. This specific 
receptor is thus used to connect the cytoskeleton with extracellular adhesive sites via the 
intermediate fibronectin [247].  It is essential for structures used in ligament tissue 
engineering to allow easy adherence by surrounding cells, in vitro and in vivo. Though it 
has been reported that PLGA films could allow more MSCs to attach compared to PLLA 
films [248], there is still no report of cell attachments on fibrous scaffolds, as physical 
geometry could possibly affect migration, adhesion and attachment of the cells.  However, 
MSCs which did not attach to fibers remained unpolarized (Fig 36).   
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Figure 35 MSCs' attachment on knitted scaffolds 
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Figure 36 MSCs in fibrin glue 
 
3.2.3       Porosity 
The porosity of current knitted scaffolds was 44% (current knitted structures, table 7). It is 
important that tissue engineering scaffolds have sufficient porosity to accommodate tissue 
regeneration and nutrient exchange following implantation. Kim and Mooney (1996) 
pointed out that it is advantageous to have a polymer construct with a large surface area to 
volume ratio [249]. Such a construct provides a conduit for uniform cell delivery and 
development of high cell density. One of their criteria for an ideal scaffold was that the 
porosity should be at least 90% in order to provide a high surface area for cell-polymer 
interactions, sufficient space for extracellular matrix (ECM) regeneration, and minimal 
diffusion constraints during in vitro culture. However, when it came to considering in 
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vivo biodegradation, scaffolds with low porosity (relatively with low surface to volume 
ratio), could possibly be an advantage as the slow degradation would keep the integrity of 
the original constructs for a longer period of time, as hydrolysis of both PLLA and PLGA 
starts from surface [250]. To balance these two considerations, the porosity of 44% 
(current knitted structures) could possibly be a better combination of these two factors.  
 






















PLLA 166.3 178.2 173.2 178.2 187.0 176.6 0.0245 16 0.392 
PLGA 126.9 119.7 122.0 124.6 124.4 123.5 0.012 8 0.096 
Scaffold 1241.6 1091.5 1041.0 963.8 919.7 1051.5 0.87 24 0.87 
 
 
3.2.4 In vitro degradation   
During the 20 weeks of immersion, pH values of the immersing medium were always 
around 7.4, except for a minute decline below 7 at week 3 (Fig 37). In general, the trace 
amount of acidic degradation products, mainly from polymers of lactic acids and glycolic 
acids, will not interrupt the internal human environment by abrupt pH drop as they are 
rapidly cleared. Even at week 3, the low pH value may not happen in a real implantation 
scenario, as the degradation products will be continuously cleared in the living system,  
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unlike the situation in our experiment where the medium was changed once a week [251]. 
The drop in pH value at week 3 was possibly due to rapid degradation of PLGA.  
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Figure 37 Change of pH value of immersion medium of PLLA/PLGA scaffolds 
 
The mass of the knitted structures decreased with time following immersion as predicted 
(Fig 38). Two statistical significances have been observed, between initial weight and all 
remaining groups as well as between weight after 4 weeks and after 20 weeks (Table 8, 
One way ANOVA, LSD, P< 0.05). The first significance could possibly be attributed to 
relatively rapid degradation of PLGA, which could also be visually testified by loss of 
blue color of the scaffolds at initial stage (Fig 39) as well as the drop in pH value at week 
3. The second significance is also reasonable. As mass loss of the scaffolds started 
gradually, it would become apparent after a certain time point, 20 weeks in this case. Blue 
PLGA yarns degraded faster than PLLA yarns as the knitted scaffolds almost lost their 
blue color after 8 weeks (Fig 39). 
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Table 8 Mass loss percentage of knitted scaffolds after immersion in medium  




Std. Error Sig. 95% Confidence Interval 
     Lower Bound Upper Bound
b .138(*) .033 .00 .066 .210 
c .166(*) .033 .00 .095 .238 
d .163(*) .033 .00 .091 .235 





f .188(*) .033 .00 .116 .259 
a -.138(*) .033 .00 -.210 -.066 
c .028 .033 .40 -.043 .100 
d .025 .033 .46 -.047 .097 
e .022 .033 .52 -.050 .094 




 f .050 .033 .16 -.022 .122 
a -.166(*) .033 .00 -.238 -.095 
b -.028 .033 .40 -.100 .043 
d -.003 .033 .92 -.075 .068 
e -.007 .033 .84 -.078 .065 




 f .021 .033 .53 -.050 .093 
a -.163(*) .033 .00 -.235 -.091 
b -.025 .033 .46 -.097 .047 
c .003 .033 .92 -.068 .075 
e -.003 .033 .92 -.075 .068 




 f .025 .033 .47 -.047 .096 
a -.160(*) .033 .00 -.231 -.088 
b -.022 .033 .52 -.094 .050 
c .007 .033 .84 -.065 .078 
d .003 .033 .92 -.068 .075 




 f .028 .033 .41 -.044 .100 
a -.188(*) .033 .00 -.259 -.116 
b -.050 .033 .16 -.122 .022 
c -.021 .033 .53 -.093 .050 
d -.025 .033 .47 -.096 .047 




 e -.028 .033 .41 -.100 .044 
 
LSD, * the mean difference is significant at the .05 level 
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The molecular weights of PLLA at different immersion durations were measured. As the 
rapidly degradable PLGA was used to promote potential tissue ingrowth at a initial stage 
of implantation as well as to provide more space for regeneration at the later stage, its 
molecular weight was not examined. Their degradation could be identified by the loss of 
blue color in the knitted scaffolds. On the other hand, they did not dissolve in chloroform, 
which was used to dissolve PLLA for the GPC test (Fig 40). Hence, the existence of 
PLGA would not interrupt PLLA’s molecular weight test. There was a descending trend 
in molecular weights of PLLA with time (Fig 41) as drop of molecular weight usually 
started earlier than mass loss [61].  However, there was no statistical significance until 12 
weeks, possibly due to small differences between different groups. Further decline in 
molecular weight at 16 and 20 weeks was attributed to the statistical significance between 














Figure 40 Graph from gel permission chromatography (GPC) of PLLA. 
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Figure 41 Changes in molecular weight 
 
Table 9 Change of molecular weight during immersion 
 original 4w 8w 12w 16w 20w 
MW 127748 123491 107043 114139 127388 110760 
 128381 122040 120637 107500 93486 89247 
 128061 114775 113490 103580 86838 70020 
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Table 10 Multiple comparisons of molecular weights (MW) 
(I) VAR (J) VAR Mean Difference Std. Error Sig. 95% Confidence Interval 
Molecular 





b 7961 10461 .461 -14832 30755 
c 14340 10461 .196 -8454 37134 
d 19657 10461 .085 -3137 42451 





 f 38054(*) 10461 .003 15261 60848 
a -7961 10461 .461 -30755 14833 
c 6379 10461 .553 -16415 29173 
d 11696 10461 .285 -11098 34489 
e 17531 10461 .120 -5262 40325 




 f 30093(*) 10461 .014 7299 52887 
a -14340 10461 .196 -37134 8454 
b -6379 10461 .553 -29172 16415 
d 5317 10461 .620 -17477 28111 
e 11153 10461 .307 -11641 33946 




 f 23714(*) 10461 .043 921 46508 
a -19657 10461 .085 -42451 3137 
b -11696 10461 .285 -34490 11098 
c -5317 10461 .620 -28111 17477 
e 5836 10461 .587 -16958 28630 




 f 18397 10461 .104 -4396 41191 
a -25493(*) 10461 .031 -48286 -2699 
b -17531 10461 .120 -40325 5262 
c -11153 10461 .307 -33946 11641 
d -5836 10461 .587 -28629 16958 




 f 12562 10461 .253 -10232 35355 
a -38054(*) 10461 .003 -60848 -15261 
b -30093(*) 10461 .014 -52887 -7299 
c -23714(*) 10461 .043 -46508 -921 
d -18397 10461 .104 -41191 4396 




 e -12562 10461 .253 -35355 10232 
 
• LSD, The mean difference is significant at the .05 level. 
 
The main parameters which influence the polymer biodegradability are polymer 
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crystallinity, hydrophilicity, composition and form of the product. PLLA degraded by 
backbone breakage caused by water penetration. This can be rephrased “as the 
hydrophilicity of the polymer is increased so is its biodegradability,” because the solvent 
in the biological media is basically water with quite a high salt content [250]. Slow 
degradation of semicrystalline PLLA due to relatively hydrophobic property could be 
attributed to its usage in the potential ligament tissue engineered structures.  
 
For tissue engineering, the ability to control the degradability of the biomaterials becomes 
critical for completion of the assigned function. The ideal rate of degradation should not 
exceed the rate of tissue regeneration, especially with regards to mechanical strength. In 
spite of the large number of investigations dealing with PLA, PGA and their copolymers, 
they still degrade at varying rates when implanted in various locations and under different 
mechanical stimuli. Recent data obtained from in vitro ageing experiments under 
physiological conditions showed that initial morphology and subsequent morphology 
changes were very important factors in determining the degradation behaviors of these 
polymers [252]. Thus current study of degradation of knitted structures remains 
meaningful after many related research investigations have been reported.   
 
Design of the current in vitro degradation experiment was based on ISO standard 13781, 
“ Poly(L-lactide) resins an fabricated forms for surgical implants-in vitro degradation 
testing”, with small revisions. Cell culture medium was used instead of standard soaking 
solution, as the current structures could possibly be immersed in it during future in vitro 
and in vivo cell loading procedures and bioreactor incubation.   
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3.2.5 Mechanical properties 
3.2.5.1 Tensile properties 
Cross-sectional areas of knitted scaffolds (Fig 42) decreased sharply in the initial 4 weeks 
and then kept relatively stable until 20 weeks (Fig 43). The data showed that PLLA fibers 
almost kept their morphological integrity for the initial 20 weeks, after quick loss of 
PLGA fibers. It was also supported by morphological study. There was a significant 
difference between cross-sectional area at the initial stage and at subsequent time points, 
but there were no significant difference between those cross-sectional areas from 4 to 20 
weeks (Table 11).   
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Table 11 Cross-sectional areas of knitted scaffolds in degradation 
 













b 24663(*) 1389 .000 21797 27529 
c 24496(*) 1389 .000 21630 27362 
d 25402(*) 1389 .000 22536 28268 
e 26914(*) 1389 .000 24048 29780 




f 26396(*) 1389 .000 23530 29262 
a -24663(*) 1389 .000 -27529 -21797 
c  -167 1389 .906 -3033 2699 
d 739 1389 .599 -2127 3605 
e 2252 1389 .118 -614 5118 
b.  Areas 
at week 4 
 
(10439) 
f 1733 1389 .224 -1133 4599 
a -24496(*) 1389 .000 -27362 -21630 
b 167 1389 .906 -2699 3033 
d 906 1389 .520 -1960 3772 
e 2418 1389 .094 -448 5284 




f 1900 1389 .184 -966 4766 
a -25402(*) 1389 .000 -28268 -22536 
b -739 1389 .599 -3605 2127 
c -906 1389 .520 -3772 1960 
e 1512 1389 .287 -1354 4378 




f 994 1389 .481 -1872 3860 
a -26914(*) 1389 .000 -29780 -24048 
b -2252 1389 .118 -5118 614 
c -2418 1389 .094 -5284 448 
d -1512 1389 .287 -4378 1354 




  f -518 1389 .712 -3384 2348 
a -26396(*) 1389 .000 -29262 -23530 
b -1733 1389 .224 -4599 1133 
c -1900 1389 .184 -4766 966 
d -994 1389 .481 -3860 1872 




  e 518 1389 .712 -2348 3384 
 




The stress-strain behavior of the scaffold displays the characteristic toe, linear, yield and 
failure regions that are typically found in stress-strain curves of tendons and 
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ligaments [20] (Fig 44). The modulus generally increased with degradation time (Fig 45 
and table 12). Similarly the ultimate tensile strength as well as strain generally decreased 
with degradation time (Fig 46 and 47, table 13). This trend has also been observed in other 
in vitro degradation studies [253, 254]. The increase in crystallinity during degradation at 
the amorphous regions are first hydrolyzed which resulted in a higher Young’s modulus 
with degradation time. The simultaneous increase in mass loss and decrease in molecular 
weight at the same time resulted in more defects within the scaffold and thus reduced the 



















Figure 44 Typical stress-strain plots of PLLA/PGLA scaffolds at different duration of 
immersion 
• linear elastic region is from 0.07 to 0.14 strains in Figure 44. 
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Figure 45 Young's modulus of the knitted scaffolds after immersion 
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Table 12 Multiple comparisons of Young's Modulus in in vitro degradation 
. 
95% Confidence Interval 









b 119(*) 25 .000 67 171 
c 101(*) 25 .001 49 154 
d 106(*) 25 .000 53 158 





f 17 25 .514 -36 69 
 a -119(*) 25 .000 -171 -67 
c -18 25 .494 -70 35 
d -13 25 .608 -66 39 
e -69(*) 25 .012 -121 -16 
b. Young’s 
Modulus at  
week 4 
(163 MPa) 
f -102(*) 25 .000 -155 -50 
a -101(*) 25 .001 -154 -49 
b 17 25 .494 -35 70 
d 4 25 .864 -48 57 





f -85(*) 25 .003 -137 -32 
a -106(*) 25 .000 -158 -53 
b 13 25 .608 -39 66 
c -4 25 .864 -57 48 





f -89(*) 25 .002 -141 -37 
a -50 25 .059 -103 2 
b 69(*) 25 .012 16 121 
c 51 25 .055 -1 104 





f -33 25 .200 -86 19 
a -17 25 .514 -69 36 
b 102(*) 25 .000 50 155 
c 84(*) 25 .003 32 137 
d 89(*) 25 .002 37 141 
f. Young’s 
Modulus at 
week 20  
(265 MPa) 
 e 33 25 .200 -19 86 
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Table 13 Multiple comparisons of tensile strength in in vitro degradation 
 












b 3.9 3.1 .227 -2.6 10.3 
c 9.8(*) 3.1 .004 3.4 16.2 
d 14.2(*) 3.1 .000 7.8 20.6 
e 23.9 (*) 3.1 .000 17.4 30.3 





 f 27.2(*) 3.1 .000 20.8 33.6 
a -3.9 3.1 .227 -10.3 2.6 
c 6.0 3.1 .067 -.5 12.4 
d 10.3 (*) 3.1 .003 3.9 16.7 
e 20.0 (*) 3.1 .000 13.6 26.5 





 f 23.3 (*) 3.1 .000 16.9 29.7 
a -9.8 (*) 3.1 .004 -16.2 -3.4 
b -6.0 3.1 .067 -12.4 .5 
d 4.4 3.1 .174 -2.1 10.8 
e 14.1(*) 3.1 .000 7.7 20.5 





 f 17.4(*) 3.1 .000 10.9 23.8 
a -14.2(*) 3.1 .000 -20.6 -7.8 
b -10.3 (*) 3.1 .003 -16.7 -3.9 
c -4.4 3.1 .174 -10.8 2.1 
e 9.7 (*) 3.1 .005 3.3 16.1 




 f 13.0 (*) 3.1 .000 6.6 19.4 
a -23.9 (*) 3.1 .000 -30.3 -17.5 
b -20.0 (*) 3.1 .000 -26.5 -13.6 
c -14.1(*) 3.1 .000 -20.5 -7.7 
d -9.7 (*) 3.1 .005 -16.1 -3.3 




 f 3.3 3.1 .302 -3.1 9.7 
a -27.2(*) 3.1 .000 -33.6 -20.8 
b -23.3 (*) 3.1 .000 -29.7 -16.9 
c -17.4(*) 3.1 .000 -23.8 -10.9 
d -13.0 (*) 3.1 .000 -19.4 -6.6 




 e -3.3 3.1 .302 -9.7 3.1 
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Figure 47 Tensile strain at break of the knitted scaffolds after immersion 
 
The initial reduction in Young’s modulus and increase in ultimate strain between week 0 
and week 4, indicated that the scaffold became less stiff but more ductile. This trend is 
contrary to that observed at subsequent degradation times, as week 0 samples were not 
immersed in the medium at 37°C prior to tensile test, which was required by ISO standard 
13781 that the initial values for all tests should be determined directly before starting the 
degradation test (time zero). The combined effect of immersion at an elevated temperature 
of 37°C in the medium could have resulted in some structural changes of the scaffold 
before the effects of hydrolysis became significant. 
 
The Young’s modulus of the scaffold at various durations of immersion in the medium 
range from 146% to 238% that of the value reported for human ACL [18]. In general, the 
Young’s modulus value for human anterior cruciate ligament is 111MPa, ultimate 
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tensile strength is at least 38MPa [18], while ultimate mechanical properties of ligaments 
generally increase during development and then diminish with aging [19]. The ultimate 
tensile strength before 12 weeks of immersion in medium satisfies the minimum reported 
strength of 38MPa, while ultimate tensile strength at 16 weeks and 20 weeks account for 
95% and 87% of it, respectively. It is possible that the new ligament tissue which 
regenerated within 12-16 weeks is sufficient to withstand the in vivo stresses as the tensile 
strength of the scaffold is reduced significantly after 16 weeks. Any compliance mismatch 
(difference in Young’s modulus) between tissue and scaffold could result in failure of the 
implant [217, 256]. However, current structures should undergo more revisions before 
clinical application as tissue engineered ligaments, such as cell loading, extracellular 
matrix deposition and collagen cross-linking, pre-conditioning, influence of mechanical 
stimuli in bioreactors, biomembrane wrap. All these procedures would possibly alter the 
final Young’s modulus and ultimate tensile strength. Hence, the results of the ultimate 
tensile strength and Young’s modulus of current constructs being similar to that of human 
ACL, would definitely advocate their future applications.  
 
The strains at failure fell between 19.4-32% after 20 weeks of immersion. There is much 
controversy about ACL strain at failure, due to the differences of mechanical procedures 
and standards of failure. Further loading beyond the toe region produces a nearly linear 
curve, when fibers lose their crimp and become parallel. The upper strain limit of this 
linear region is 2-5% and then collagen fiber failure begins at 7-8% strain—[257]. The 
maximum strain that a ligament can endure before failure is between12-15% strains [258]. 
A further 20-40% apparent linear region was reported after previous maximum strain 
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when the properties of whole ligaments were examined [259], while there were several 
possible artifacts in the testing technique. First, the initial failure of a small number of 
collagen fibers was not detected when it didn’t decrease the load carrying ability of the 
ligament as a whole. Second, the measurement of the slippage between the grips provides 
an overestimation of the true tissue strain in the absence of high speed video recording. 
Third, preconditioning to align the individual fibers and different strain rates used in 
different experiments also contributed the differences [260, 261]. The current results 
almost match that of normal ACL, when ligaments were tested as a whole 
 
3.2.5.2 Viscoelastic properties 
The stress needed to sustain a constant elongation decreased with time (Fig.48) and the 
strain required to sustain a constant load increased with time (Fig.49) indicating that the 
scaffold behaves in a viscoelastic manner under mechanical loading, similar to normal 
ACLs [260-262]. Table 14 shows the viscoelastic properties of the scaffold obtained from 
the relaxation test. The data from the constant load creep test were analyzed in a similar 
manner to the relaxation test (Table 15). The purpose of using normalized stress and strain 
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Figure 48 Stress relaxation curve of PLLA/PLGA scaffold with initial strain of 2.5% 
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Table 14 Viscoelastic quantities from the relaxation test  
Initial Stress Final Stress Normalized Stress 
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(MPa) (MPa) Relaxation Rate (1/ln(s)) 
3.4 ± 0.3 2.1 ± 0.3 -0.041 ± 0.009 
 






Creep Rate (1/ln(s)) 
0.016 ± 0.002 0.018 ± 0.002 0.013 ± 0.001 
 
The normalized stress relaxation rate is obtained by finding the slope of the normalized 
stress vs ln(t) strain plot. The normalized stress is obtained by dividing the stress values 
by the initial stress immediately. The logarithmic operation on the time axis transformed 
the inherently nonlinear relation in load decay vs time into a linear relation such that a 
simple linear regression could be used to determine the rates of relaxation. 
 
The normalized stress relaxation rate obtained (-0.041 /ln(s)) is comparable to that 
obtained by Donahue et al [263] in their study of anterior cruciate ligament (ACL) grafts 
made from bovine digital extensor (-0.038 /ln(s)) and human hamstring tendons (-0.036 
/ln(s)). The normalized strain creep rate (0.013 /ln(s)), however, is lower than that 
obtained although it is of the same order of magnitude. Normalized strain creep rate for 
bovine digital extensor is 0.029 1/ln(s) and that for human hamstring tendons is 0.025 
1/ln(s). The difference is probably due to the different testing methodologies and the fact 
that different materials are used (i.e. biological samples vs polymeric scaffold). However, 
the proximity of the values indicates that the PLLA/PLGA scaffold is possibly a 
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viable implant for ACL regeneration in terms of viscoelastic behavior. 
 
Over the past 10 years, huge efforts were made to develop biomaterials that could be 
considered as “ideal” scaffolds for cell growth, however, few have reached clinical 
efficacy.  Regardless of the source or type of biomaterials, they have to be biocompatible 
and mechanically compatible with native tissues to fulfill their desired role. A few of them 
have been reported suitable for ligament tissue engineering, when both appropriate 
mechanical properties and general requirements from tissue engineering are required 
[264]. 
 
The knitted PLLA/PLGA structures developed here can fulfill many of the requirements 
proposed for prospective candidates in ligament tissue engineering, with regards to 
porosity, cell attachment, degradation rate and mechanical properties.  However, more 
research has to be carried out to improve and revise the mechanical properties of current 
knitted scaffolds before they can finally been used in clinical practice. 
 
3.3 Rabbit ACL reconstruction 
3.3.1 Fate of implanted cultured rabbit MSC  
MSCs were fully stained and retained their previous morphology before 
transplantation (Fig 50). During the staining procedure, a small amount of MSCs (10-20%) 
detached. It was noticeable that not all MSCs were stained with the same intensity.  
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Figure 50 cFDA stained MSCs (100x) 
Note: left pictures show normal morphology of MSC while fluorescence from cFDA 
stained MSC was found under fluorescent microscope. 
 
Previous studies had reported the survivability of donor cells implanted in knee joints. 
These donor cells can survive for up to 4 to 6 weeks [234-236]. Unlike our study, these 
studies were performed with different cell sources, animal models and implantation sites. 
It would be difficult to make comparisons, as the donor cells may have differences in 
immunological response, potential blood supply and fascia protection, etc. Since our 
results showed that MSCs have the best potential as a cell source for tissue engineering 
applications, it was necessary to determine the fate of heterologous MSCs when used in 
the repair and regeneration of ACL. Implanted allogeneic MSC had been reported to play 
an essential role in graft facilitation in an allogeneic environment [265]. It has also been 
shown to exhibit a suppressive effect on T-lymphocyte responses in an in vitro study by 
Klyushnenkova et al (1998) [266]. Therefore, it is likely that implanted allogeneic MSCs 
should only face a mild immunological response and the probability of survival in an 
allogeneic environment should also be relatively good. This was demonstrated in this 
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After eight weeks’ implantation, the cFDA stained MSCs could still be found in both 
group II (MSC loading, Fig 51) and group III (MSC loading and fascia cover, Fig 52). The 
acquired results matched those of previous publications. In natural anatomy, the ACL is 
an intra-articular and extra-synovial structure, which is covered by a synovial membrane 
isolating it from the synovial fluid. A simple break in the synovial covering may lead to 
destruction of the ligament’s integrity through exposure to the synovial fluid environment 
and also by compromising the vascular supply [267]. The pedicle fascia used in this study 
was supposed to provide the extra protective covering for loading MSCs while preventing 
the MSCs from diffusing into the knee joint as the fibrin glue usually degrades in one 
week [268].  
 
   
Figure 51 cFDA stained MSCs after 8 weeks' implantation from group II (MSCs) 
Left picture shows section of scaffolds after 8 weeks’ implantation. Note the varying 
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cross-sections of knitted scaffolds. In right picture, fluorescence denotes the cFDA stained 
MSCs around the scaffolds. 
   
Figure 52 cFDA stained MSCs after 8 weeks' implantation (group III, MSCs and fascia) 
Left picture shows section of scaffolds after 8 weeks’ implantation. In right picture, 
fluorescence denotes the cFDA stained MSCs around the scaffolds. 
 
 
3.3.2 Considerations in scaffold design  
Though both Young’s modulus and maximal tensile strength were lower than that of 
normal ACL, both of them could still meet the basic requirements of ACL reconstruction 
in a 20 week in vitro degradation test, partly because biological tissues are subjected to 
forces ranging from 10% to 25% of their braking loads in normal conditions [261]. Based 
on previous experiences with knitted scaffolds, diameters of knitted scaffolds will increase 
with fibroblasts ingrowths when implanted in vivo [269]. In the meantime, there was 
neither increment in the initial cross-sectional area of graft nor tightening of grafts 
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resulting in superior graft properties, whereas, however, larger grafts would lead to 
increased cartilage degeneration, osteogenesis, and flexion contractures [270]. On the 
other aspect, maximal tensile strength of PLLA scaffolds used for ACL reconstruction 
would be expected to increase with time [37], possibly due to fibroblasts in-growth and 
subsequent functionality, but unlike what happened in vitro, the maximal tensile strength 
dropped over time due to degradation of polymers [126]. Based on all these knowledge, 
we tried to employ structures with diameters smaller than normal, to reconstruct ACLs to 
avoid the consequent increase in diameters, which would inevitablely increase pressure on 
knee cartilage and deterioration so as to meet the basic requirements for ACL 
reconstruction. One potential drawback of a knitted structure is that the whole structure 
will collapse when any one slot breaks. To circumvent it, two independent fine knitted 
scaffolds were chosen, instead of a larger one, as the scaffolds would not only undergo 
degradation and mechanical stress in vivo, but would also face difficulties going through 
bone tunnels and being sutured to the periosteum. All these activities would potentially 
break some of the fibers, even the yarns of scaffolds, which ultimately could cause the 
collapse of the whole structure.  
 
In our previous study, the knitted PLLA/PGLA scaffolds were found to be non-
toxic and had good porosity as well as cell adhesion property. In a 20-week in vitro 
degradation test, both maximal mechanical strength and Young’s modulus of the knitted 
scaffolds could meet the basic requirements of ACL reconstruction. In the design of  
scaffold for this study, small overall diameter scaffolds were used to reconstruct ACLs 
instead of larger ones, for the following three reasons: 1) Cummings et al (2002) had 
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shown that by increasing the initial graft cross-sectional area or having taut grafts will not 
improve graft mechanical properties, while larger grafts would lead to increased cartilage 
degeneration, osteogenesis, and flexion contractures [270];  2) diameters of knitted 
scaffolds would increase with fibroblast ingrowths when implanted in vivo [269]; 3) 
maximal tensile strength of PLLA scaffolds used for ACL reconstruction would increase 
with time [37], possibly due to fibroblast in-growth and subsequent functionality [126], 
but unlike what happened in vitro, the maximal tensile strength dropped over time due to 
degradation of polymers.  
 
When compared with ACL reconstruction using cross-linked collagen in a similar 
rabbit experiment [271], survival rates of current constructs was higher and they incurred 
less immuno-response. Though no mature collagen bundle has been reported in tissue 
engineered ACL research, there are many reports on relatively more mature ACL 
regeneration, such as formation of collagen fibers, orientations and crimps.[128, 177] Two 
reasons could be attributed to inferior collagen fiber formation and orientations in the 
current study; first, PLLA has inferior ability to encourage fibroblasts to attach and 
function, mainly due to lack of a RGD sequence in collagen [146]; second, the relatively 
short implantation period impede further maturation of ingrowth fibroblasts and 
extracellular matrix, when compared with a 48 weeks [177] or one year study [35].   
 
Though PLLA and PGLA have long been regarded as biocompatible biomaterials, the 
knitted scaffolds made of these biomaterials have to be tested again due to potential 
contamination from fiber production and knitting procedure. Though results from 
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tetrazolium-based colorimetric assay (MTT) in previous studies had shown that the knitted 
structures were free of contamination, further in vivo in situ study was still necessary to 
examine the host’s response.  
 
3.3.3 Histology of tissue engineered ACL 
The foreign body reaction to biomaterials is theoretically inevitable, which include foreign 
body giant cells and the components of granulation tissue: macrophages, fibroblasts and 
capillaries in varying amounts depending on the form and topography of the implanted 
materials [272]. Macrophages and capillaries were difficult to find in all of histological 
samples. Possible explanations were that the PLLA and PGLA used were quite 
biocompatible and did not induce a significant immune response, as well as knee joints 
being a special environment lacking conditions for the growth of capillaries.  
 
3.1.3.1 Histology at 4 week 
The presence of clear synovial fluid, good topography of cartilage surface and no visible 
granulation formation around the structures indicated that no strong foreign body reactions 
and chronic inflammation reactions were caused by knitted scaffolds (Fig 51), while 
prosthetic ligament inevitably caused synovitis [272]. On the other aspect, no morphologic 
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Figure 53 Frontal view of knee joint 4 weeks after ACL reconstruction with scaffolds  
 
After 4 weeks’ implantation, in-growth of fibroblasts and small amount of extracellular 
matrix could be found around the yarns of scaffolds (Fig 54). There was no difference 
among different groups, except that there were paralleled fibroblasts and well layered 
mature extracellular matrix in out-layers of tissue engineered ligament from group III and 
IV (Fig 55), which came from fascia wrap used.  
 
  
   117                              
------------------------------------ RESULTS AND DISCUSSION --------------------------------- 
 
 
Figure 54 Histology of tissue engineered ligament at 4 weeks (Group I, H&E staining, 
100x) 
Note: irregular transparent forms (s) were cross-section of yarns of scaffolds 
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3.1.3.2 Histology at 20 weeks 
The rate of degradation of PLLA has been reported to vary from 40 weeks to over 3 years 
depending on the molecular weight, size and shape of the implant [273]. Polymers in knee 
joints would usually degrade much faster than in bone tunnels, as a result of greater 
mechanical stress on the reconstructed ACL caused by multiform motion of the knee joint, 
which was also supported by the evidence that PLGA fibers in knee joints degraded faster 
than in bone tunnels. In fact, a 10-month lifespan is enough for ACL regeneration. The 
risk is that drop in mechanical strength drops before mass loss will affect the whole 
structure. In our current study, there was no visible sign of PLLA fiber degradation at 20 
weeks, in agreement with previous research on braided PLLA scaffolds used for ACL 
reconstruction [177, 273].  
 
The fibroconnective tissue ingrowth around the PLLA fibers occurred similarly in all four 
groups. The loose design of the knitted structures seemed to promote and support tissue 
growth. In contrast, carbon fibers and Dacron induced fibrous-tissue formation only to the 
outer sheet of the implants [274, 275]. When compared with braided structures, higher 
porosities of knitted structures could encourage more tissues to grow, though no 
quantitative comparison has been done between the two structures.  
 
The normal anterior cruciate ligaments are parallel bands of regularly orientated, dense 
connective tissue connecting the femur and tibia, which are surrounded by a mesentery-
like fold of synovium [10]. Fascia was used to wrap the constructs in some groups to 
mimic the normal structures. Although we are unsure of the actual roles of fascia 
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covers, we know that they could contribute formation of dense outer layers of tissue 
engineered ligaments after 20 weeks as well as improve collagen excretion significantly. 
In microanatomy, the normal ACLs are made up of multiple fascicles (100-250μm in 
diameter), of which the basic unit is collagen. Parallel and inter-linked fascicles were 
obvious in normal histology (Fig 56 and 57), but not seen in any experimental group (Fig 
58-61), as the collagen fibrils or fibers were not matured to be grouped into fascicles after 




Figure 56 Normal ACL histology (H&E, 100x) 
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Figure 57 Normal ACL histology (H&E, 200x) 
 
 
Figure 58 Histology of tissue engineered ACL from group I (H&E, 100x) 
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Figure 59 Histology of tissue engineered ACL from group II (H&E, 100x) 
 
 
Figure 60 Histology of tissue engineered ACL from group III (H&E, 100x) 
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Figure 61 Histology of tissue engineered ACL from group IV (H&E, 100x) 
 
3.3.4 Histology in bone tunnel 
The strength of the fixation of the implant at either end of the drill channel is crucial for 
long-term success, since the interface between a synthetic material and a living tissue is a 
region of high stress [276]. The normal ACL insertion zone (Fig 62) has material 
properties that are intermediate between ligament and bone. Its function is to transmit load, 
distribute and decrease stress concentration at the attachment site [277]. Although the 
ideal way is to reconstruct the normal transition, conventional tendon transfers are unable 
to restore this complex anatomy of ACL insertion within the first 6 months [1]. The 
fibrous tissue formation within the bone tunnel could possibly transforms into a “normal” 
insertion with the four-zonal structure after a long time [278]. Introduction of large 
amounts of MSCs to the bone tunnel have shown to improve the healing of tendon to bone 
at the insertion zone, through formation of fibrocartilagenous attachment at early stages 
[224]. However, it will be more difficult for tissue engineered ligament, especially 
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when the number of loading MSCs in our current study was much lower than that reported 
for tendon healing in the bone tunnel. In all four groups, similar ligament to bone healing 
was observed with tissue engineered ligaments attached to bone by intermediated 
fibroblasts (Fig 63). Insufficient integration strength and compliance mismatch with host 
tissue are possible reasons for scenarios whereby the tissue engineered ligaments were 
pulled out through the bone tunnel during mechanical tests. 
 
 
Figure 62 Normal ligament to bone transition (H&E, 100x) 
L denotes ligament (ACL); T denotes transition from ligament to bone; B denotes bone. 
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Figure 63 Healing of tissue engineered ligament to bone (H&E, 100x) 
 




Collagen being a key component in ligaments provides high tensile strength to withstand 
physiological loads during activities of daily living. It accounts for 70-80% of the tissue 
dry weight. Type I collagen is about 8 to 9 times far more abundant than type III collagen 
in ligament tissues, while other collagens such as types V, VI and XII occur in small 
amounts. The ultimate fibril diameter attained during fibrillogenesis appears to depend on 
the quantitative ratio in which the type I and type III collagens are secreted during fibril 
polymerization [238] . Hence, it is important to evaluate the secreted collagen that will be 
used in ligament repair and regeneration, to determine the existence of type I and type III 
collagen in the tissue.  
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In normal ACLs, collagen I staining (Fig 64) was much stronger than that of collagen III 
(Fig 65). Composition of collagen III will significantly increase during injury [237]. In 
specimens from experimental group, as collagen III staining significantly increased, there 
was no significant difference between collagen I (Fig 66) and collagen III staining (Fig 
67). This trend was observed across all experimental groups. 
 
 
Figure 64 Collagen I staining of normal ACL (100x) 
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Figure 65 Collagen III staining of normal ACL (100x) 
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Figure 67 Collagen III staining of tissue engineered ACL (100x) 
  
The white fascicles, cross-section of PLLA yarns, were surrounded by fibroblast ingrowth 
and ECM which were stained by collagen antibodies.    
 
3.3.6 Western blot analysis 
Bradford Protein Assay
Calibration













Figure 68 Calibration curve of Bradford protein assay 
 
In four experimental groups and normal control, two bands of collagen type I 
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were obvious at 210k and 95k respectively, though the densities were different among 
different groups (Fig 69). The amount of collagen I in group III (146.7%) and IV (163.3%) 
were higher than in group II (75.1%) and normal control (100%) while there was no 
significance between group III and IV, as well as between group II and normal control. 
Collagen I in group I (20.5%) was significantly lower than that in all other groups (Table 
16, One-way ANOVA, P<0.05) (Fig 70).  
 
 
Figure 69 Western blot of collagen I from group I, II, III, IV and normal control 
 
 Arrows indicate collagen, Type I detected by α-collagen (I) (Calbiochem) 
significantly at 95 kDa and 210 kDa. 











Figure 70 Quantitative expression of collagen I expression in different groups 
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Table 16 Multiple comparisons of collagen I expressions 
95% Confidence Interval 
Group Group Mean Difference 
Std. 




b -157206(*) 37211 .000 -232749 -81663 
c -363793(*) 37211 .000 -439337 -288250 
d -411990(*) 37211 .000 -487533 -336447 
a. OD in 
group I 
(59903) 
e -228814(*) 37211 .000 -304357 -153271 
a 157206(*) 37211 .000 81663 232749 
c -206588(*) 37211 .000 -282131 -131045 
d -254784(*) 37211 .000 -330327 -179242 
b. OD in 
group II 
(217109) 
e -71608 37211 .062 -147151 3935 
a 363793(*) 37211 .000 288250 439336 
b 206588(*) 37211 .000 131044 282131 
d -48197 37211 .204 -123740 27346 
c. OD in 
group III 
(423697) 
e 134979(*) 37211 .001 59436 210522 
a 411990(*) 37211 .000 336447 487533 
b 254784(*) 37211 .000 179241 330327 
c 48197 37211 .204 -27346 123740 
d. OD in 
group IV 
(471893) 
e 183176(*) 37211 .000 107633 258720 
a 228814(*) 37211 .000 153271 304358 
b 71608 37211 .062 -3935 147151 




d -183176(*) 37211 .000 -258719 -107633 
 
LSD The mean difference is significant at the .05 level. 
 
In all groups, bands of collagen type III at 110 and 290 kDa were obtained with other 
minor bands, ranging from 63 kDa to 300 kDa (Fig 71). Collagen III expression in group 
III (137.1%) and IV (162.9%) were higher than all other groups, while there was no 
significance between them. Collagen III expression in group II (71.4%) was lower than 
that in normal control, but higher than group I (20.5%) significantly (Table 17, One-way 
Anova, P<0.05) (Fig 72).  
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Figure 71 Western blot of collagen III from group I, II, III, IV and normal control 
 Arrows indicate collagen, Type III detected by α-collagen (III) (Oncogene 
Research Products) significantly at 110 kDa and 290 kDa. 
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Table 17 Multiple comparisons of collagen III expressions 
95% Confidence Interval 
Group Group Mean Difference 
Std. 




b -144581(*) 37305 .000 -220314 -68849 
c -330307(*) 37305 .000 -406040 -254574 
d -403349(*) 37305 .000 -479081 -327616 
a. OD in 
group I 
(57867) 
e -225272(*) 37305 .000 -301005 -149539 
a 144581(*) 37305 .000 68849 220314 
c -185726(*) 37305 .000 -261458 -109993 
d -258767(*) 37305 .000 -334500 -183035 
b. OD in 
group II 
(202449) 
e -80691(*) 37305 .037 -156423 -4958 
a 330307(*) 37305 .000 254574 406040 
b 185726(*) 37305 .000 109993 261458 




e 105035(*) 37305 .008 29302 180768 
a 403349(*) 37305 .000 327616 479081 
b 258767(*) 37305 .000 183035 334500 
c 73042 37305 .058 -2691 148774 
d. OD in 
group IV 
(461216) 
e 178077(*) 37305 .000 102344 253809 
a 225272(*) 37305 .000 149539 301005 
b 80691(*) 37305 .037 4958 156423 




d -178077(*) 37305 .000 -253809 -102344 
 
LSD, *  The mean difference is significant at the .05 level. 
 
Our results showed that MSC seeding obviously improved excretion of collagen 
type I and type III. It is postulated that donor cells may help to recruit more progenitor 
/reparative cells by interacting with host cells, while excreting extracellular matrix [50]. 
For the authors, it is the first evidence to quantitatively analyze cell seeding effect on in 
vivo protein components for tissue engineering of ACL reconstruction, though many 
reports on in vitro protein analysis have been published [279]. Fascia wrap has been 
reported to contribute to the formation of well-oriented fibroblasts and extracellular 
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matrix, as well as improving mechanical properties [37, 177], though it could not provide 
good mechanical support when used separately [280]. In the current study, fascia wraps 
did improve protein synthesis and potentially functionality, but it was not clear about the 
exact ratio of protein which fascia wraps brought to protein synthesis from regeneration. 
Though fascia wraps have shown stronger effects on collagen excretion than MSC seeding 
in the current study, further study is necessary when the quantity of fascia wraps and 
number of seeding cells are well controlled. Longer implantation time and larger animal 
models are necessary to evaluate their exact roles. The ultimate fibril diameter attained 
during fibrillogenesis appears to depend on the quantitative ratio in which the type I and 
type III collagens are secreted during fibril polymerization [238]. In the future, it would be 
worthwhile to determine the ratio of collagen I and III in the same specimen, and establish 
their roles in the healing process. 
 
3.3.7 Mechanical properties 
3.3.7.1 Maximal tensile loads 
Of all the specimens tested, the failure mode of two reconstructed ACLs (one from 
group II and the other from group IV) was dislodgement from the bone tunnels. In all 
other cases, the ACL constructs failed in the mid-substance inside the knee joint. However, 
the exact location of rupture was inconsistent, since multiple ruptures occurred at different 
places simultaneously. Though sometimes, certain scaffolds seemed intact, rupture of 
microfibers may have taken place at various spots, causing a drastic drop in tensile load.  
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Maximal tensile loads of tissue engineered ligaments were 9.2%, 9.8%,13.9% and 
10.4% of normal in groups I, II, III and IV, respectively (see Table 18), however, there 
was no significant difference between the different groups (Table 19, One-way ANOVA, 
p<0.05).  
 
Table 18 Maximal tensile loads of tissue engineered ligaments after 20 weeks' 
implantation 
N=5 Maximal tensile load (N) 
Group I 14+/- 7.8 
Group II 14.9+/- 6.6 
Group III 20.9+/-4.5 
Group IV 15.8+/- 6.8 
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Table 19 Multiple comparisons of maximal tensile loads 
95% Confidence Interval 









b -.9 6.9 .902 -15.3 13.6 
c -6.9 6.9 .331 -21.4 7.6 
d -1.8 6.9 .798 -16.2 12.7 
a. tensile load 
in group I 
(14N) 
e -137.8 (*) 6.9 .000 -152.2 -123.4 
a .9 6.9 .902 -13.6 15.3 
c -6.0 6.9 .394 -20.5 8.4 
d -.9 6.9 .893 -15.4 13.5 
b. tensile load 
in group II 
(14.9N) 
e -137.0(*) 6.9 .000 -151.4 -122.5 
a 6.9 6.9 .331 -7.6 21.4 
b 6.0 6.9 .394 -8.4 20.5 
d 5.1 6.9 .470 -9.4 19.6 
c. Tensile load 
in group III 
(20.9N)  
e -130.9 (*) 6.9 .000 -145.4 -116.5 
a 1.8 6.9 .798 -12.7 16.3 
b .9 6.9 .893 -13.5 15.4 
c -5.1 6.9 .470 -19.6 9.4 
d. Tensile load 
in group IV 
(15.8N) 
  e -136.0 (*) 6.9 .000 -150.5 -121.6 
a 137.8 (*) 6.9 .000 123.4 152.3 
b 137.0(*) 6.9 .000 122.5 151.4 




d 136.0 (*) 6.9 .000 121.6 150.5 
 
           LSD, the mean difference is significant at the .05 level. 
 
3.3.7.2 Stiffness 
Stiffness of tissue engineered ligaments in groups I, II, III and IV were 9.1%, 
18.7%, 16.7% and 13.1% of normal respectively (see Table 20). All of them were 
significantly lower than the normal value while there was no significant difference in the 
data between the individual experimental groups (Table 21, one-way ANOVA, p < 0.05).  
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Table 20 Stiffness of tissue engineered ligaments after 20 weeks' implantation 
N=5 Stiffness (N/mm) 
Group I 8.6+/-2.3 
Group II 7.8+/-3.2 
Group III 8.4+/-2.2 
Group IV 7.4+/-3.4 
Normal control 50.4+/-5.3 
   
 
Table 21 Multiple comparisons of stiffness 
95% Confidence Interval 









b .8 2.2 .711 -3.8 5.4 
c .2 2.2 .938 -4.4 4.8 
d 1.2 2.2 .595 -3.4 5.8 
a. Stiffness 
in group I 
(8.6N/mm) 
e -41.8(*) 2.2 .000 -46.4 -37.2 
a -.8 2.2 .711 -5.4 3.8 
c -.7 2.2 .770 -5.2 3.9 
d .4 2.2 .871 -4.2 5.0 
b. Stiffness 
in group II 
(7.8N/mm) 
e -42.6 (*) 2.2 .000 -47.2 -38.0 
a -.2 2.2 .938 -4.8 4.4 
b .7 2.2 .770 -3.9 5.2 
d 1.0 2.2 .650 -3.6 5.6 
c. Stiffness 
in group III 
(8.4N/mm) 
e -42.0(*) 2.2 .000 -46.6 -37.4 
a -1.2 2.2 .595 -5.8 3.4 
b -.4 2.2 .871 -5.0 4.2 
c -1.0 2.2 .650 -5.6 3.6 
d. Stiffness 
in group IV 
(7.4N/mm) 
e -43.0(*) 2.2 .000 -47.6 -38.4 
a 41.8(*) 2.2 .000 37.2 46.4 
b 42.6 (*) 2.2 .000 38.0 47.2 




d 43.0(*) 2.2 .000 38.4 47.6 
LSD, *  The mean difference is significant at the .05 level. 
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Maximal tensile load and stiffness are important parameters for tissue engineered ACL 
[281]. Though MSC seeding and fascia wrap are effective to improve collagen excretion 
and possibly regeneration, none of them could improve maximal tensile load and stiffness 
of current tissue engineered ligaments significantly. The acquired maximal tensile loads 
and stiffness were mainly from the partially degraded PLLA fibers, while regenerated 
tissues were not well oriented and far from functionality. In other words, the excreted 
collagen still could not form enough collagen fibrils/bundles as well as orientate and 
cross-link appropriately to undertake mechanical force. So they have shown little effect on 
maximal tensile load and stiffness at the current stage.   
 
3.3.7.3 Strain and Cross-section 
The cross section areas of tissue engineered ligaments from group 1, 2, 3, and 4 were 
48.9%, 106.4%, 68.1% and 14.9% respectively (Fig 73). Though the crosssectional areas 
of cell loading groups (Group 2 and 3) were higher than cell free groups (Group 1 and 4), 
there was no significance between them due to a relatively high variation (Table 22 and 
23). Possibly the loading cells could promote more regeneration due to more chemotoxin 
excreted, when compared with cell free groups. More results are necessary to evaluate and 
draw conclusions.  
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Figure 73 Cross section areas of tissue engineered ligaments 
 













group 1 2.0 2.0 0.8 5.9 0.7 
group 2 3.5 2.8 3.2 0.2 15.5 
group 3 1.3 0.3 11.9 2.5 0.2 
group 4 0.3 1.8 0.6 0.2 0.4 
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Table 23 Multiple comparisons of cross-sectional areas 
95% Confidence Interval 










b -2.8 2.3 .241 -7.5 2.0 
c -1.0 2.3 .679 -5.7 3.8 
d 1.6 2.3 .486 -3.1 6.4 
a. areas in 
group I 
(2.3mm2) 
e -2.4 2.3 .310 -7.1 2.4 
a 2.8 2.3 .241 -2.0 7.5 
c 1.8 2.3 .440 -3.0 6.6 
d 4.4 2.3 .069 -.4 9.1 
b. areas in 
group II  
(5.0 mm2) 
 e .4 2.3 .869 -4.4 5.1 
a 1.0 2.3 .679 -3.8 5.7 
b -1.8 2.3 .440 -6.6 3.0 
d 2.6 2.3 .272 -2.2 7.3 
c. areas in 
group III  
(3.2 mm2) 
e -1.4 2.3 .541 -6.2 3.3 
a -1.6 2.3 .486 -6.4 3.1 
b -4.4 2.3 .069 -9.1 .4 
c -2.6 2.3 .272 -7.3 2.2 
d. areas in 
group IV  
(0.7 mm2) 
e -4.0 2.3 .095 -8.8 .8 
a 2.4 2.3 .310 -2.4 7.1 
b -.4 2.3 .869 -5.1 4.4 
c 1.4 2.3 .541 -3.3 6.2 
e. areas in 
normal ACL 
(4.7 mm2) 
 d 4.0 2.3 .095 -.8 8.8 
   
 
Though ACLs are viscoelastic, more than 6% of strain will not recover fully and lead to 
elongation and loss of functionalities [65]. Hence, it is necessary for tissue engineered 
ligaments to exactly match the viscoelastic properties of ACLs. In current clinical practice, 
autografts are often used, which will undergo elongation possibly due to enzymatic 
degradation in vivo [262]. The viscoelastic properties of tissue engineered ligaments came 
from both knitted structures and PLLA polymer chains [282]. It was noticeable that gauge 
lengths from two cell loading groups, group 2 and 3, were less than the other two 
experimental groups (Fig 74). There was no significance between either one from 
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group 1, 2, 3, 4 and normal ACLs (Table 24), though there was significance between 
group 1 and 2, between group 2 and 4, as well as between group 3 and 4 (Table 25). In 
general, the gauge lengths were acceptable in all experimental groups, as there was no 


















Figure 74 Gauge lengths of tissue engineered ligaments 
 
Table 24 Gauge length of tissue engineered ligaments 
mm Specimen 1 Specimen 2 Specimen 3 Specimen 4 Specimen 5 
group 1 12.0 10.6 10.6 8.0 5.2 
group 2 8.2 4.6 7.8 6.0 4.8 
group 3 8.8 9.3 5.3 4.4 5.3 
group 4 7.9 10.8 9.2 9.0 15.2 





   140                              
------------------------------------ RESULTS AND DISCUSSION --------------------------------- 
 
Table 25 Multiple comparisons of gauge lengths 
95% Confidence Interval 










b 3.0(*) 1.4 .041 .1 5.9 
c 2.7 1.4 .067 -.2 5.5 
4 -1.1 1.4 .416 -4.0 1.7 
a. Length in 
group I 
(9.3mm) 
e 1.1 1.4 .449 -1.8 3.9 
a -3.0(*) 1.4 .041 -5.9 -.1 
c -.3 1.4 .807 -3.2 2.5 
d -4.1(*) 1.4 .007 -7.0 -1.3 
b. Length in 
group II 
(6.3mm) 
 e -1.9 1.4 .173 -4.8 .9 
a -2.7 1.4 .067 -5.5 .2 
b .3 1.4 .807 -2.5 3.2 
d -3.8(*) 1.4 .012 -6.7 -.9 
c. Length in 
group III 
(6.6mm) 
 e -1.6 1.4 .257 -4.5 1.3 
a 1.1 1.4 .416 -1.7 4.0 
b 4.1(*) 1.4 .007 1.3 7.0 
c 3.8(*) 1.4 .012 .9 6.7 
d. Length in 
group IV 
(10.4mm) 
 e 2.2 1.4 .124 -.7 5.1 
a -1.1 1.4 .449 -3.9 1.8 
b 1.9 1.4 .173 -.9 4.8 
c 1.6 1.4 .257 -1.3 4.5 
e. Length in 
Normal ACL 
(8.1mm) 
 d -2.2 1.4 .124 -5.1 .7 
 
LSD, the mean difference is significant at the .05 level. 
 
The knitted scaffolds could support tissue in-growth and improved structures with greater 
maximal load will potentially serve as good tissue engineered ligaments. Ultimately, a 
longer implantation course is necessary for denser fibroblast ingrowth as well as for the 




   141                              
------------------------------ CONCLUSION AND FUTURE DIRECTION ---------------------- 
 
4 Conclusion and future direction  
 
Mesenchymal stem cells were found to be a better cell source than ACL and MCL 
fibroblasts in this study, with regards to proliferation, collagen excretion as well as 
collagen expression profiles (Collagen I, collagen III and alpha smooth muscle actin). The 
Young’s modulus of knitted scaffolds could possibly meet the minimal requirements for 
ACL reconstruction in the first twenty weeks. The knitted scaffolds could survive after 20 
weeks’ implantation when used in ACL reconstruction. Mesenchymal stem cells and 
fascia lata covers could possibly promote ligament regeneration, with regards to 
mechanical strength, cross-sectional areas and histology.  Fibroblasts were not well 
oriented and there was no collagen bundle formation. In general, fascia wrap and MSCs 
were found to have potential for ligament tissue engineering. However, in consideration of 
the challenge and complexity of ligament tissue engineering, more techniques and 
understanding of ligament regeneration would be necessary for future success in making 
functional tissue engineered ligaments. 
 
4.1 Growth factors, bioreactors and gene therapy 
Ligament healing is a complex and highly-regulated process that is initiated, sustained and 
eventually terminated by a variety of molecules. Growth factors represent one of the most 
important biomolecules involved in healing. IGF-I, TGF-beta, vascular VEGF, PDGF, and 
bFGF have been reported to be markedly up-regulated following ligament injury and are 
active at multiple stages of the healing process. They are involved in the proliferation and 
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migration of fibroblasts and/or to subsequently leading to increase collagen production, 
and/or angiogenesis, and/or the production of other growth factors [283].    
 
As the lack of blood supply after ACL ruptures is one of the main reasons to block 
subsequent ligament regeneration, controlled angiogenesis should theoretically be 
beneficial. As VEGF has long been regarded to have strong influence on blood supply, it 
may be beneficial to introduce it at both bone tunnels as well as mid-substance of tissue 
engineered ligaments [283, 284].   
 
As well-controlled mechanical and biochemical parameters are essential for potential 
ligament regeneration both in vivo and in vitro, bioreactors are sure to contribute [76]. 
More knowledge about exact roles, effective pathways, necessary duration of growth 
factors, optimized parameters of mechanical stimuli, as well as/or controlled gene 
regulation, is necessary for future progress. Side effects from gene therapy, growth factor 
controlled delivery and bioreactor should be avoided while all these procedures should be 
simplified and done with good quality control.  
 
4.2  In vivo collagen cross-link 
Collagen V which increased after ligament injuries has been reported to possibly inhibit 
the larger collagen bundle formation and further functionality [285]. After more 
understanding about the exact role of collagen V in ligament regeneration, its role would 
be well controlled. Except for growth factor delivery, more attention would be paid to 
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promote the maturity of excreted extracellular matrix to allow collagen bundle formation 
and cross-link between them before they can be functional [144, 286-288].  
 
4.3  Inhibit harsh environment  
There were significant changes in cytokine profiles after ACL injuries, which could lead 
to the difficulties of ACL regeneration [38]. Unfortunately until now the exact roles and 
pathway of each cytokine are not clear. It has been hypothesized that ACL regeneration is 
better accomplished if we have better ways to control these cytokines.    
4.4  Larger animal models and stronger scaffolds 
Although large amount of ligament relevant research have been done using rabbit model, 
there are still lots of limitations on broad usage of rabbit models. Their relatively small 
knee joint size restricts accurate drilling, which is essential for functional reconstruction 
[289].  Their knee joints could not really mimic normal mechanics in human beings, who 
can extend their knee joints further. Goat or pig model should be adopted while more 
accurate bone tunnel drilling techniques could be used, such as computer-assisted surgery.  
 
Ideal tissue engineered ACL prostheses should match normal ACLs in maximal tensile 
strength, Young’s Modulus, viscoelastic properties and diameters. Stronger scaffolds 
should be used, possibly with the incorporation of braided cord to improve maximal load. 
It will mimic normal knee joint physiology by using a prosthesis, which has same 
mechanical properties of a normal ACL, to reconstruct at initial time. Notchplasty could 
be done just like in human cases if necessary. To further improve cell-attaching 
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surface in the scaffolds and potentially improve micro-environments for ingrowth cells’ 
proliferation and differentiation, electrospun nanofibers could be used [290] 
 
4.5 Proposed design improvement of scaffold for ligament tissue engineering 
 
As mentioned above, no satisfactory results have been reported on a scaffold with good 
initial mechanical properties, controlled degradation and biocompatibility when used for 
in vivo ACL reconstruction.  Currently, it is postulated that an ideal structure to meet the 
basic requirements should be a dual structure (Fig 75). The two ends of the dual structure 
should be induced for osteogenesis and integrated with host bone after implantation, while 
the middle part of it should have host tissue ingrowth and achieve subsequent 
functionality with time.   
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Figure 75 Schematic structure of composite scaffold for ACL reconstruction 
 
A: Composite structure biodegradable scaffold, with both ends being osteo-inductive and 
the middle portion having potential for ligament/tendon tissue formation/regeneration. 
B: Cell-seeded composite scaffold with proliferative potential and/or reparative cells 
recruited into the scaffold with regenerative potential. 
C: Cells in two ends will be induced to form bone and integrate with host bone, while cells 
in middle part will express extracellular matrix (ECM).  
 
 
From a cross-sectional view, it could be a multiple layered structure while individual 
layers take on different functions as well as degrade at different rates (Fig 76).  At initial 
stage (A), the outlayer of the structure is a biomembrane which could block the 
inflammatory cytokines and other macromolecules from knee joints while allowing 
nutrient ion exchange. The middle layer is a loose structure to provide a good micro-
environment for tissue ingrowth as well as subsequent functionality. The growth factors 
originally kept in the middle layer will be released to promote faster tissue ingrowth. The 
core of the ideal structure is made of multiple intact layers, which would take the 
necessary mechanical strength for ACL reconstruction and degrade layer by layer. The 
changes of mechanical properties would be moderate and be offset by functionality in the 
middle layer. Thus, the general mechanical properties of the structure will remain stable 
during degradation and match that of the ACL. The growth factors which are kept inside 
the core of the ideal structure, mainly to promote blood supply and tissue functionality, 
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will be released at a later stage at a stable rate. This improved design of scaffold for 
ligament tissue engineering has been filed for patent application.  
 
 
Figure 76 Cross-sectional view of composite structure for ACL reconstruction 
The cross-sectional views of the three individual layers in the composite scaffold are 
shown in degradation. They are (1) protective cover (outlayer); (2) porous nano-
structures and (3) strong internal cord. The irregularly-shaped structures found within the 
porous nano-structural region are the transplanted and/or reparative cells. Growth factor 
molecules shown here in “open triangle” on porous nanostructures will be released at 
early stage. Growth factor molecules (closed circle) encapsulated in the internal cord will 
be released while internal cord degrades in later stage.  
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4.6 Innervations of tissue engineered ligaments 
Stretch-sensitive mechanoreceptors in the ligaments of the knee trigger muscle 
contractions that protect the knee from extremes of motion [39]. Reconstructive 
procedures may restore the structural role of ligaments, but traumatic loss of 
proprioception is most likely permanent under current therapy. In future, a functional 
ACL should have normal reflex arcs to protect the human knee.  
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